Document:

Warrant Purchase Agreement dated as of April 21, 2010

 Exhibit 10.1 

CORCEPT THERAPEUTICS INCORPORATED 

WARRANT PURCHASE AGREEMENT 

This Warrant Purchase Agreement (“Agreement”) is made as of April 21, 2010 (the “Effective
Date”), by and among Corcept Therapeutics Incorporated, a Delaware corporation (the “Company”), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached
as Exhibit A hereto (the “Schedule of Purchasers”). Such persons and entities are hereinafter collectively referred to herein as “Purchasers” and each individually as a “Purchaser”.

 AGREEMENT 

In consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the
receipt of which is hereby acknowledged, the Company and each Purchaser (severally and not jointly) hereby agree as follows: 
 SECTION
1.  AUTHORIZATION OF SALE OF SECURITIES. 
 The Company has authorized the sale and issuance of
warrants in the form of Exhibit B hereto (each a “Warrant” and collectively, the “Warrants”) to purchase an aggregate of up to 4,408,773 shares of its common stock, par value $0.001 per share (the
“Common Stock”), on the terms and subject to the conditions set forth in this Agreement. 
 SECTION 2.  AGREEMENT
TO SELL AND PURCHASE THE WARRANTS. 
 2.1     Sale of Warrants.   At
the Closing (as defined in Section 3), the Company will sell to each Purchaser, and each Purchaser will purchase from the Company, a Warrant to purchase the number of shares of Common Stock set forth opposite such Purchaser’s name on the
Schedule of Purchasers (such shares of Common Stock, the “Underlying Shares”). Such number of Underlying Shares shall be equal to that number of shares such Purchaser purchases on or prior to the Closing pursuant to such
Purchaser’s exercise of its warrant, dated October 16, 2009 (the “October 2009 Warrant”), issued to it pursuant to the Securities Purchase Agreement, dated October 12, 2009 (the “Securities Purchase
Agreement”), among the Company and each of the persons named on Schedule I thereto. The aggregate purchase price for the Warrants purchased by each Purchaser is set forth opposite such Purchaser’s name on the Schedule of Purchasers.

 2.2     Separate Agreement.   Each Purchaser shall severally, and not
jointly, be liable for only the purchase of the Warrants that appear on the Schedule of Purchasers that relate to such Purchaser. The Company’s agreement with each of the Purchasers is a separate agreement, and the sale of Warrants to each of
the Purchasers is a separate sale. The obligations of each Purchaser hereunder are expressly not conditioned on the purchase by any or all of the other Purchasers of the Warrants such other Purchasers have agreed to purchase. 

 SECTION 3. CLOSING AND DELIVERY. 

3.1     Closing.   The closing of the purchase and sale of the Warrants (which
Warrants are set forth in the Schedule of Purchasers) pursuant to this Agreement (the “Closing”) shall be held on April 21, 2010 at the offices of Latham & Watkins LLP, 140 Scott Drive, Menlo Park, California 94025, or
on such other date and place as may be agreed to by the Company and the Purchasers. At or prior to the Closing, each Purchaser shall execute any related agreements or other documents required to be executed hereunder, dated as of the date of the
Closing (the “Closing Date”). 
 3.2     Issuance of the Warrants at the
Closing.   At the Closing, the Company shall issue to each Purchaser a Warrant registered in the name of such Purchaser, or in such nominee name(s) as designated by such Purchaser, representing the number of Underlying Shares as set
forth in the Schedule of Purchasers. The name(s) in which the Warrant is to be issued to each Purchaser are set forth in the Purchaser Questionnaire and the Selling Stockholder Notice and Questionnaire in the forms attached hereto as Appendix I and
II (the “Purchaser Questionnaire” and the “Selling Stockholder Questionnaire”, respectively), as completed by each Purchaser, which shall be provided to the Company no later than the Closing Date. The Warrants shall
be delivered to each Purchaser promptly following the Closing Date, but in any event within 10 business days following the Closing Date. 

3.3     Delivery of the Registration Rights Agreement.   At the Closing, the Company
and each Purchaser shall execute and deliver the Registration Rights Agreement in the form attached hereto as Appendix III (the “Registration Rights Agreement”), with respect to the registration of the Underlying Shares under the
Securities Act of 1933, as amended (the “Securities Act”). 
 SECTION 4.   REPRESENTATIONS, WARRANTIES AND
COVENANTS OF THE COMPANY. 
 Except as set forth on the Schedule of Exceptions delivered to the Purchasers
concurrently with the execution of this Agreement (the “Schedule of Exceptions”), the Company hereby represents and warrants as of the date hereof to, and covenants with, the Purchasers as follows: 

4.1     Organization and Standing.   The Company has been duly incorporated and is
validly existing as a corporation in good standing under the laws of Delaware, has full corporate power and authority to own or lease its properties and conduct its business as presently conducted, and is duly qualified as a foreign corporation and
in good standing in all jurisdictions in which the character of the property owned or leased or the nature of the business transacted by it makes qualification necessary, except where the failure to be so qualified would not have a material adverse
effect on the business, properties, financial condition or results or operations of the Company (a “Material Adverse Effect”). The Company has no subsidiaries or equity interest in any other entity. 

4.2     Corporate Power; Authorization.   The Company has all requisite corporate
power, and has taken all requisite corporate action, to execute and deliver this Agreement, the 
  

 2 

 
Warrants and the Registration Rights Agreement (as defined below and collectively, the “Transaction Documents”), sell and issue the Warrants and carry out and perform all of its
obligations under the Transaction Documents. Each Transaction Document constitutes the legal, valid and binding obligation of the Company, enforceable in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors’ rights generally, (ii) as limited by equitable principles generally, including any specific performance and (iii) with respect to the
Registration Rights Agreement, as rights to indemnity or contribution may be limited by state or federal laws or public policy underlying such laws. The execution and delivery of the Transaction Documents do not, and the performance of the
Transaction Documents and the compliance with the provisions of the Transaction Documents and the issuance, sale and delivery of the Warrants and the Underlying Shares by the Company will not conflict with, or result in a breach or violation of the
terms, conditions or provisions of, or constitute a default under, or result in the creation or imposition of any lien pursuant to the terms of, the Company’s Amended and Restated Certificate of Incorporation, as amended and as in effect on the
date hereof (the “Certificate of Incorporation”), the Company’s Amended and Restated Bylaws, as amended and as in effect on the date hereof (the “Bylaws”), or any statute, law or rule (including federal and
state securities laws and the rules and regulations of the NASDAQ Capital Market (the “Principal Market”)) applicable to the Company or regulation or any state or federal order, judgment or decree applicable to the Company or any
indenture, mortgage, lease or other material agreement or instrument to which the Company is a party or any of its properties is subject. 

4.3     Issuance and Delivery of the Warrants.   The Warrants have been duly
authorized and, when issued and paid for in compliance with the provisions of this Agreement, will be validly issued, fully paid and nonassessable. The Underlying Shares have been duly authorized and, upon exercise of the Warrants in accordance with
their terms, including payment of the exercise price therefor, will be validly issued, fully paid and nonassessable. The issuance and delivery of the Warrants is not subject to preemptive, co-sale, right of first refusal or any other similar rights
of the stockholders of the Company or any liens or encumbrances which have not been validly waived or complied with. Assuming the accuracy of the representations made by each Purchaser in Section 5, the offer and issuance by the Company of the
Warrants is exempt from registration under the Securities Act. 
 4.4     SEC Documents;
Financial Statements.   The Company has filed in a timely manner all documents that the Company was required to file with the Securities and Exchange Commission (the “Commission”) under Sections 13, 14(a) and 15(d) the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), since becoming subject to the requirements of the Exchange Act. As of their respective filing dates (or, if amended prior to the date of this Agreement, when
amended), all documents filed by the Company with the Commission (the “SEC Documents”) complied in all material respects with the requirements of the Exchange Act and the rules and regulations of the Commission promulgated
thereunder. None of the SEC Documents as of their respective dates contained any untrue statement of material fact or omitted to state a material fact required to be stated therein or necessary to make the statements made therein, in light of the
circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Documents (the “Financial Statements”) comply as to form in all material respects with applicable accounting
requirements and with the published rules and regulations of the Commission with respect thereto. The Financial Statements have 

 

 3 

 
been prepared in accordance with United States generally accepted accounting principles consistently applied and fairly present the financial position of the Company at the dates thereof and the
results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal, recurring adjustments). Except as disclosed in the SEC Documents, since December 31, 2009, the Company has not altered
materially its method of accounting or the manner in which it keeps its accounting books and records. Except as disclosed in the SEC Documents, the Company has not declared or made any dividend or distribution of cash or other property to its
stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock (other than in connection with repurchases of unvested stock issued to employees of the Company). The Company has not issued any equity
securities to any officer, director or affiliate, except (a) Common Stock issued pursuant to existing Company stock option or stock purchase plans or executive and director corporate arrangements disclosed in the SEC Documents, (b) Common
Stock issued pursuant to other existing agreements disclosed in the SEC Documents or (c) otherwise as disclosed in the SEC Documents. The Company has no liabilities or obligations required to be disclosed in the SEC Documents that are not so
disclosed in the SEC Documents, which, individually or in the aggregate, would have or reasonably be expected to have a Material Adverse Effect. 

4.5     Capitalization.   All of the Company’s outstanding shares of capital
stock have been duly authorized and validly issued and are fully paid and nonassessable, have been issued in compliance with all federal and state securities laws, and were not issued in violation of or subject to any preemptive right or other
rights to subscribe for or purchase securities. The authorized capital stock of the Company consists of 140,000,000 shares of common stock and 10,000,000 shares of undesignated Preferred Stock. As of the Effective Date, there are no shares of
Preferred Stock issued and outstanding and there are 62,744,967 shares of Common Stock issued and outstanding, of which no shares are owned by the Company. There are no other shares of any other class or series of capital stock of the Company issued
or outstanding. The Company has no capital stock reserved for issuance, except that, as of the Effective Date, there are 9,200,372 shares of Common Stock reserved for issuance pursuant to warrants outstanding on such date, and 7,346,636 shares of
Common Stock reserved for issuance pursuant to options outstanding on such date pursuant to the Company’s 2000 Stock Option Plan and Amended and Restated 2004 Equity Incentive Plan. There are 2,658,781 shares of Common Stock available for
future issuance under the Company’s Amended and Restated 2004 Equity Incentive Plan and no shares of Common Stock available for future issuance under the Company’s 2000 Stock Option Plan. There are no bonds, debentures, notes or other
indebtedness having general voting rights (or convertible into securities having such rights) (“Voting Debt”) of the Company issued and outstanding. Except as stated above, there are no existing options, warrants, calls,
subscriptions or other rights, agreements, arrangements or commitments of any character, relating to the issued or unissued capital stock of the Company, obligating the Company to issue, transfer, sell, redeem, purchase, repurchase or otherwise
acquire or cause to be issued, transferred, sold, redeemed, purchased, repurchased or otherwise acquired any capital stock or Voting Debt of, or other equity interest in, the Company or securities or rights convertible into or exchangeable for such
shares or equity interests or obligations of the Company to grant, extend or enter into any such option, warrant, call, subscription or other right, agreement, arrangement or commitment. The issuance of Common Stock or other securities pursuant
to any provision of this Agreement or the Warrants will not give rise to any preemptive rights or rights of first refusal on behalf of any Person or result in the triggering of any anti-dilution or other similar rights, except as provided herein.

  

 4 

 
Except as disclosed in the SEC Documents and as provided herein, there are no agreements or arrangements under which the Company is obligated to register the sale of any of their securities under
the Securities Act. There are no securities or instruments containing anti-dilution provisions that will be triggered by the issuance of the Warrants or the Underlying Shares. The Company has made available upon request of the Purchasers, a true,
correct and complete copy of the Certificate of Incorporation and the Bylaws. 
 4.6
    Litigation.   There are no legal or governmental actions, suits or other proceedings pending or, to the Company’s Knowledge, threatened against the Company before or by any court, regulatory body or
administrative agency or any other governmental agency or body, domestic, or foreign, which actions, suits or proceedings, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect. The Company is not a party
to or subject to the provisions of any injunction, judgment, decree or order of any court, regulatory body, administrative agency or other governmental agency or body that might have a Material Adverse Effect. “Knowledge” shall mean the
knowledge of the Company’s executive officers. 
 4.7     Governmental
Consents.   No consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state, or local governmental authority on the part of the Company is required in
connection with the consummation of the transactions contemplated by this Agreement or the Registration Rights Agreement except for (a) the filing of a Form D with the Commission under the Securities Act and compliance with the securities and
blue sky laws in the states and other jurisdictions in which shares of Common Stock are offered and/or sold, which compliance will be effected in accordance with such laws, (b) the approval by the Principal Market of the listing of the
Underlying Shares and (c) the filing of one or more registration statements and all amendments thereto with the Commission as contemplated by the Registration Rights Agreement. 

4.8     No Default or Consents.   Neither the execution, delivery or performance of
the Transaction Documents by the Company nor the consummation of any of the transactions contemplated thereby (including the issuance and sale by the Company of the Warrants and the Underlying Shares) will give rise to a right to terminate or
accelerate the due date of any payment due under, or conflict with or result in the breach of any term or provision of, or constitute a default (or an event which with notice or lapse of time or both would constitute a default) under, or require any
consent or waiver under, or result in the execution or imposition of any lien, charge or encumbrance upon any properties or assets of the Company pursuant to the terms of, any indenture, mortgage, deed of trust or other agreement or instrument to
which the Company is a party or by which the Company or any of its properties or businesses is bound, or any franchise, license, permit, judgment, decree, order, statute, rule or regulation applicable to the Company or violate any provision of the
Certificate of Incorporation or the Bylaws, except in each case as would not cause, either individually or in the aggregate, a Material Adverse Effect, and except for such consents or waivers which have already been obtained and are in full force
and effect. 
 4.9     No Material Adverse Change.   Except as disclosed in
the Schedule of Exceptions or in the SEC Documents, since December 31, 2009, there have not been any changes in the authorized capital, assets, liabilities, financial condition, business, Material Agreements or operations of the Company from
that reflected in the Financial Statements except changes in the 
  

 5 

 
ordinary course of business which have not had, either individually or in the aggregate, a Material Adverse Effect. 

4.10     No General Solicitation.   Neither the Company, nor any of its affiliates,
nor any Person acting on its or their behalf, has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D promulgated under the Securities Act) in connection with the offer or sale of the Warrants.

 4.11     No Integrated Offering.   None of the Company, any of its
affiliates or any Person acting on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would adversely affect reliance by the Company on
Section 4(2) of the Securities Act or require registration of any of the Warrants under the Securities Act or cause this offering of the Warrants to be integrated with prior offerings by the Company for purposes of the Securities Act or any
applicable stockholder approval provisions, including under the rules and regulations of the Principal Market. 

4.12     Sarbanes-Oxley Act.   To the Company’s Knowledge, the Company is in
material compliance with the requirements of the Sarbanes-Oxley Act of 2002 that are effective and applicable to the Company as of the date hereof, and the rules and regulations promulgated by the Commission thereunder that are effective and
applicable to the Company as of the date hereof. 
 4.13     Patents and Trademarks.
  To the Company’s Knowledge, the Company has or has rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, copyrights, licenses and other similar rights that are necessary or
material for use in connection with their respective businesses as described in the SEC Documents and which the failure to so have could, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect
(collectively, the “Intellectual Property Rights”). Except as set forth in the SEC Documents, the Company has not received a written notice that the Intellectual Property Rights used by the Company violates or infringes upon
the rights of any Person. Except as set forth in the SEC Documents, to the Company’s Knowledge, all such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual
Property Rights. 
 4.14     Listing and Maintenance Requirements.   Except
as specified in the SEC Documents, the Company has not, in the two years preceding the date hereof, received notice from the Principal Market to the effect that the Company is not in compliance with the listing or maintenance requirements
thereof. Except as disclosed in the SEC Documents, the Company is in compliance with the listing and maintenance requirements for continued listing of the Common Stock. The issuance and sale of the Warrants under this Agreement does not
contravene the rules and regulations of the Principal Market and no approval of the stockholders of the Company thereunder is required for the Company to issue and deliver to the Purchasers the Warrants. 

4.15     Disclosure.   The Company understands and confirms that the Purchasers will
rely on the foregoing representations and covenants in effecting transactions in securities of the Company. To the Company’s Knowledge, all due diligence materials regarding the Company, its business and the transactions contemplated
hereby, furnished by or on behalf of the Company to the Purchasers or their representatives upon their request are, when taken together with the SEC 

 

 6 

 
Documents, true and correct in all material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made
therein, in light of the circumstances under which they were made, not misleading. The Company confirms that neither it nor any of its officers or directors nor any other Person acting on its or their behalf has provided, and it has not authorized
any other party to provide, any Purchaser or its respective agents or counsel with any information that it believes constitutes or could reasonably be expected to constitute material, non-public information except insofar as the existence,
provisions and terms of this Agreement and the proposed transactions hereunder may constitute such information. The Company understands and confirms that each of the Purchasers will rely on the foregoing representations in effecting transactions in
securities of the Company as contemplated by this Agreement. No event or circumstance has occurred or information exists with respect to the Company or its business, properties, operations or financial conditions, which, under applicable law, rule
or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed, except for the announcement of this Agreement and related transactions and as may be disclosed in the Current Report
on Form 8-K filed by the Company. 
 4.16     Contracts.   (a) Each
indenture, contract, lease, mortgage, deed of trust, note agreement, loan or other agreement or instrument of a character that is required to be described or summarized in the SEC Reports or to be filed as an exhibit to the SEC Reports under the
Securities Act and the rules and regulations promulgated thereunder (collectively, the “Material Contracts”) is so described, summarized or filed. 

(b)     The Material Contracts to which the Company is a party have been duly and validly authorized,
executed and delivered by the Company and constitute the legal, valid and binding agreements of the Company, enforceable by and against the Company in accordance with their respective terms, except as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization or other similar laws relating to enforcement of creditors’ rights generally, and general equitable principles relating to the availability of remedies, except as rights to indemnity or contribution may be
limited by federal or state securities laws. 
 4.17     Properties and Assets.
  The Company has good and marketable title to all the properties and assets described as owned by it in the Company’s financial statements, free and clear of all liens, mortgages, pledges or encumbrances of any kind except
(i) those, if any, reflected in such consolidated financial statements or (ii) those that are not material in amount and do not adversely affect the use made and proposed to be made of such property by the Company. The Company holds its
leased properties under valid and binding leases. The Company owns or leases all such properties as are necessary to its operations as now conducted. 

4.18     Compliance.   The Company (a) is in compliance in all material
respects with all applicable laws, rules, regulations, orders, decrees and judgments applicable to it, including any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the
environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Applicable Laws”), (b) has received all material permits, licenses or other approvals required under Applicable Laws to conduct its business
and (c) is in compliance in all material respects with all terms and conditions of any such permit, license or approval. Except as disclosed in the SEC Documents, there are no material costs or liabilities associated

  

 7 

 
with Applicable Laws, including any capital or operating expenditures required for clean-up, closure of properties or compliance with Applicable Laws or any permit, license or approval, any
related constraints on operating activities and any potential liabilities to third parties. The Company has not received any notice of purported or actual material non-compliance with Applicable Laws nor, except to the extent it would not
individually or in the aggregate reasonably be expected to have a Material Adverse Effect, any notice of any material, actual or proposed changes in the existing Applicable Laws. The Company has not received any communication from any governmental
authority (i) threatening to revoke any permit, license, franchise, certificate of authority or other governmental authorization, or (ii) threatening or contemplating revocation or limitation of, or which would have the effect of
prohibiting or limiting the Company’s business as is currently conducted in any material respect. The Company is not subject to any claim relating to any Applicable Laws which claim has had or would reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect, and, to the Company’s Knowledge, there is no pending or threatened investigation that might lead to such a claim. 

4.19     Taxes.   The Company has filed on a timely basis (giving effect to
extensions) all required federal, state and foreign income and franchise tax returns and has paid or accrued all taxes shown as due thereon, and the Company does not have any Knowledge of a tax deficiency that has been or might be asserted or
threatened against it that could have a Material Adverse Effect. All tax liabilities accrued through the date hereof have been adequately provided for on the books of the Company. 

4.20     Transfer Taxes.   On the Closing Date, all stock transfer or other taxes
(other than income taxes) that are required to be paid in connection with the sale and transfer of the Warrants to be sold to the Purchaser hereunder will have been fully paid or provided for by the Company and all laws imposing such taxes will have
been fully complied with. 
 4.21     Investment Company.   The Company is
not an “investment company” or an “affiliated person” of, or “promoter” or “principal underwriter” for an investment company, within the meaning of the Investment Company Act of 1940, as amended, and the rules
and regulations of the Commission promulgated thereunder, and shall conduct its business in a manner so that it will not become required to be registered as an “investment company” under the Investment Company Act. 

4.22     Insurance.   The Company maintains insurance underwritten by insurers of
recognized financial responsibility, of the types and in the amounts that the Company reasonably believes is adequate for businesses, including Directors’ and Officers’ liability insurance and insurance covering all real and personal
property owned or leased by the Company against theft, damage, destruction, acts of vandalism and all other risks customarily insured against, with such deductibles as are customary for companies in the same or similar business, all of which
insurance is in full force and effect. The Company has not received any written notice of cancellation of such insurance or that the Company will not be able to renew its existing insurance coverage as and when such coverage expires. The Company
believes it will be able to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business. 
  

 8 

 4.23     Price of Common Stock.
  Neither the Company nor, to its Knowledge, any of its affiliates has taken, directly or indirectly, any action designed to or which has constituted or which might reasonably be expected to cause or result, under the Exchange Act or
otherwise, in the stabilization or manipulation of the price of any securities of the Company to facilitate the sale or resale of the Underlying Shares and the Warrants. 

4.24     Governmental Permits, Etc.   The Company has all franchises, licenses,
certificates and other authorizations from such federal, state or local government or governmental agency, department or body that are currently necessary for the operation of the business of the Company as currently conducted, except where the
failure to posses currently such franchises, licenses, certificates and other authorizations is not reasonably expected to have a Material Adverse Effect. 

4.25     Internal Control over Financial Reporting; Sarbanes-Oxley Matters.   The
Company maintains internal control over financial reporting (as such term is defined in paragraph (f) of Rule 13a-15 under the Exchange Act) as required by Rule 13a-15 under the Exchange Act. The Company is in compliance in all material
respects with all applicable provisions of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated thereunder. The Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure
controls and procedures as of the end of the period covered by its most recently filed quarterly or annual periodic report under the Exchange Act (such date, the “Evaluation Date”). The Company presented in its most recently filed
quarterly or annual periodic report under the Exchange Act the conclusions of the certifying officers about the effectiveness of the Company’s disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the
Evaluation Date, there has been no change in the Company’s internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that has materially affected, or is reasonably likely to materially affect, the
Company’s internal control over financial reporting. 
 4.26     Foreign Corrupt
Practices.   The Company, nor, to the Knowledge of the Company, any director, officer, agent, employee or other Person acting on behalf of the Company has, in the course of its actions for, or on behalf of, the Company (i) used
any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from
corporate funds; (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to
any foreign or domestic government official or employee. 
 4.27     Employee
Relations.   The Company believes that its relations with its employees are good. No executive officer of the Company (as defined in Rule 501(f) promulgated under the Securities Act) has notified the Company that such officer
intends to leave the Company or otherwise terminate such officer’s employment with the Company. No executive officer of the Company is, or is now expected to be, in violation of any material term of any employment contract, confidentiality,
disclosure or proprietary information agreement, non-competition agreement, or any other agreement or any restrictive covenant involving or otherwise affecting such executive officer’s relationship with the Company, and the continued employment
of each 
  

 9 

 
such executive officer does not subject the Company to any liability with respect to any of the foregoing matters. 

4.28     ERISA.   The Company is in compliance in all material respects with all
presently applicable provisions of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder (herein called “ERISA”); no “reportable event” (as
defined in ERISA) has occurred with respect to any “pension plan” (as defined in ERISA) for which the Company would have any liability; the Company has not incurred and does not expect to incur liability under (i) Title IV of ERISA
with respect to termination of, or withdrawal from, any “pension plan”; or (ii) Sections 412 or 4971 of the Internal Revenue Code of 1986, as amended, including the regulations and published interpretations thereunder (the
“Code”); and each “Pension Plan” for which the Company would have liability that is intended to be qualified under Section 401(a) of the Code is so qualified in all material respects and nothing has occurred,
whether by action or by failure to act, which would cause the loss of such qualification. 
 4.29
    OFAC.   Neither the Company nor, to the Company’s Knowledge, any director, officer, agent, employee or affiliate of the Company is currently subject to any U.S. sanctions administered by the Office of
Foreign Assets Control of the U.S. Treasury Department (“OFAC”), and the Company will not intentionally directly or indirectly use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any
joint venture partner or other person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC. 

4.30     Transactions with Affiliates.   Except as disclosed in the SEC Documents
and as contemplated pursuant to this Agreement, none of the officers or directors of the Company and, to the Knowledge of the Company, none of the employees of the Company is presently a party to any transaction with the Company or to a presently
contemplated transaction (other than for services as employees, officers and directors) that would be required to be disclosed pursuant to Item 404 of Regulation S-K promulgated under the Securities Act. There is no transaction, arrangement, or
other relationship between the Company and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in the SEC Documents and is not so disclosed and would have or reasonably be expected to have a Material
Adverse Effect. 
 4.31     Shell Company Status.   The Company is not a
shell company, and is not, and has never been, an issuer identified in Rule 144(i)(1). 
 4.32
    Application of Takeover Protections; Rights Agreements.   Except as disclosed in the SEC Documents, the Company has not adopted any stockholder rights plan or similar arrangement relating to accumulations of
beneficial ownership of Common Stock or a change in control of the Company. The Company and its board of directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison
pill (including any distribution under a rights agreement) or other similar anti-takeover provision under the Company’s certificate of incorporation or other organizational documents or the laws of the jurisdiction of its incorporation or
otherwise which is or could become applicable to any Purchaser solely as a result of the transactions contemplated by this Agreement. 
  

 10 

 4.33     No Additional Agreements.
  The Company does not have any agreement or understanding with any Purchaser with respect to the transactions contemplated by this Agreement other than as specified in this Agreement. 

4.34     Compliance in Clinical Trials.   The clinical trials conducted by or on
behalf of the Company that are described in the SEC Documents, investor presentations, exhibits, documents incorporated by reference and annexes thereto (the “Clinical Documents”) or the results of which are referred to in the
documents relating to this Agreement and the purchase of the Warrants, if any, are the only clinical trials currently being conducted by or on behalf of the Company. Nothing has come to the attention of the Company that has caused the Company to
believe that such studies and tests were and, if still pending, are being, conducted not in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and applicable local, state and
federal laws, rules, regulations and guidances, including the principles of Good Clinical Practice, the Federal Food, Drug and Cosmetic Act and implementing regulations at 21 C.F.R. Parts 50, 54, 56, 58 and 312, and has made all reports, filings and
notifications required thereunder, including the reports required by 21 C.F.R. § 312.32; the descriptions of the results of such studies, tests and trials contained in the Clinical Documents, if any, are not inconsistent with such results in
any material respects. Except as described in the Clinical Documents, no results of any other studies or tests have come to the attention of the Company that have caused the Company to believe that such results call into question the results
described in the Clinical Documents of the clinical trials. The Company has not received any notices or correspondence from the FDA or any other governmental agency requiring the termination, suspension or modification of any clinical trials
currently conducted by, or on behalf of, the Company or in which the Company has participated that are described in the Clinical Documents, if any, or the results of which are referred to in the Clinical Documents. Nothing has come to the attention
of the Company that has caused the Company to believe that the clinical trials previously conducted by or on behalf of the Company while conducted by or on behalf of the Company, were not conducted in accordance with experimental protocols,
procedures and controls pursuant to accepted professional scientific standards; the descriptions of the results of such studies, tests and trials contained in the Clinical Documents, if any, are not inconsistent with such results. 

SECTION 5.  REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PURCHASERS. 

5.1     Each Purchaser, severally and not jointly, represents and warrants to and covenants with the
Company that: 
 (a)     Purchaser, taking into account the personnel and resources it can
practically bring to bear on the purchase of the Warrants contemplated hereby, is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to investments in securities presenting an investment decision
like that involved in the purchase of the Warrants, including investments in securities issued by the Company, and has requested, received, reviewed and considered all information Purchaser deems relevant (including the SEC Documents) in making an
informed decision to purchase the Warrants. 
  

 11 

 (b)     Purchaser is acquiring the Warrants pursuant to
this Agreement in the ordinary course of its business and for its own account for investment only and with no present intention of distributing any of such Warrants or any arrangement or understanding with any other persons regarding the
distribution of such Warrants, except in compliance with Section 5.1(c). 
 (c)
    Purchaser will not, directly or indirectly, offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the securities purchased hereunder
except in compliance with the Securities Act, applicable blue sky laws, and the rules and regulations promulgated thereunder. 

(d)     Purchaser has, in connection with its decision to purchase the Warrants, relied with respect
to the Company and its affairs solely upon the SEC Documents and the representations and warranties of the Company contained herein. 

(e)     Purchaser is an “accredited investor” within the meaning of Rule 501 of Regulation
D promulgated under the Securities Act or a Qualified Institutional Buyer within the meaning of Rule 144A promulgated under the Securities Act. 

(f)     Purchaser has full right, power, authority and capacity to enter into this Agreement and the
Registration Rights Agreement and to consummate the transactions contemplated by this Agreement and the Registration Rights Agreement and has taken all necessary action to authorize the execution, delivery and performance of this Agreement and the
Registration Rights Agreement. Upon the execution and delivery of this Agreement and the Registration Rights Agreement by Purchaser, this Agreement and the Registration Rights Agreement shall each constitute a valid and binding obligation of
Purchaser, enforceable in accordance with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting the enforcement of creditors’ rights generally,
(ii) as limited by equitable principles generally, including any specific performance and (iii) with respect to the Registration Rights Agreement, as rights to indemnity or contribution may be limited by state or federal laws or public
policy underlying such laws. 
 (g)     Except as disclosed in the Purchaser Questionnaire,
Purchaser is not a broker or dealer registered pursuant to Section 15 of the Exchange Act (a “registered broker-dealer”) and is not affiliated with a registered broker-dealer. Purchaser is not party to any agreement for
distribution of any of the Warrants. 
 (h)     Purchaser shall have completed or caused to
be completed and delivered to the Company at no later than the Closing Date, the Purchaser Questionnaire and the Selling Stockholder Questionnaire for use in preparation of the Registration Statement (as defined in the Registration Rights
Agreement), and the answers to the Purchaser Questionnaire and the Selling Stockholder Questionnaire are true and correct in all material respects as of the date of this Agreement and will be true and correct as of the Closing Date and the effective
date of the Registration Statement; provided that the Purchasers shall be entitled to update such information by providing notice thereof to the Company before the effective date of such Registration Statement. 

 

 12 

 (i)     Purchaser agrees that until such time as the
Exercised Shares may be sold pursuant to Rule 144 under the Securities Act (“Rule 144”) without any restriction as to the manner of sale or the number of securities as of a particular date that can then be immediately sold, it will
resell the Exercised Shares only pursuant to the registration statement on Form S-3 (Registration No. 333-163140) (the “2009 PIPE Registration Statement”), in a manner described under the caption “Plan of
Distribution” in the 2009 PIPE Registration Statement and in a manner in compliance with all applicable securities laws, including, without limitation, any applicable prospectus delivery requirements of the Securities Act and the insider
trading restrictions of the Exchange Act. If the Exercised Shares are not sold pursuant to the 2009 PIPE Registration Statement in the manner described under the caption “Plan of Distribution” in the 2009 PIPE Registration Statement,
Purchaser agrees to deliver the Exercised Shares to the Company’s transfer agent to enable the transfer agent to affix any appropriate restrictive legends and to institute stop transfer instructions if appropriate. Purchaser agrees that
Latham & Watkins LLP is entitled to rely on its representations, warranties and covenants in this Agreement in connection with the opinion such firm is rendering pursuant to Section 7.3 hereof. 

5.2     Purchaser represents, warrants and covenants to the Company that except pursuant to the
exercise of its October 2009 Warrant as contemplated hereby, Purchaser has not, either directly or indirectly through an affiliate, agent or representative of the Company, engaged in any transaction in the securities of the Company subsequent to
October 16, 2009, except as set forth in filings required to be made by the Purchaser with the Commission pursuant to Section 16 of the Exchange Act or in written notice to the Company delivered prior to the date of this Agreement.
Purchaser represents and warrants to and covenants with the Company that Purchaser has not engaged and will not engage in any short sales of the Company’s Common Stock prior to the effectiveness of the Registration Statement (either directly or
indirectly through an affiliate, agent or representative). 
 5.3     Purchaser understands
that nothing in this Agreement or any other materials presented to Purchaser in connection with the purchase and sale of the Warrants constitutes legal, tax or investment advice. Purchaser has consulted such legal, tax and investment advisors as it,
in its sole discretion, has deemed necessary or appropriate in connection with its purchase of the Warrants. 

5.4     Legends. 

(a)     Purchaser understands that, until such time as the Underlying Shares have been sold pursuant
to the Registration Statement or the Warrants may be sold pursuant to Rule 144 without any restriction as to the number of securities as of a particular date that can then be immediately sold, the Underlying Shares may bear one or more legends in
substantially the following form and substance: 
 “THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT
BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND SUCH OTHER SECURITIES LAWS. NEITHER 
  

 13 

 
THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED, HYPOTHECATED OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO A TRANSACTION WHICH IS EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS, AND IN THE CASE OF A TRANSACTION EXEMPT FROM, OR
NOT SUBJECT TO, SUCH REGISTRATION, UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT AND SUCH OTHER APPLICABLE LAWS.” 

It is understood that the Warrants may bear one or more legends in substantially the following form and
substance: 
 “THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE U.S.
SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER APPLICABLE SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE UPON AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH OTHER SECURITIES LAWS.
NEITHER THIS SECURITY NOR ANY INTEREST OR PARTICIPATION HEREIN MAY BE REOFFERED, SOLD, ASSIGNED, TRANSFERRED, PLEDGED, ENCUMBERED, HYPOTHECATED OR OTHERWISE DISPOSED OF, EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT
OR PURSUANT TO A TRANSACTION WHICH IS EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, IN EACH CASE IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS, AND IN THE CASE OF A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION, UNLESS THE
COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSACTION DOES NOT REQUIRE REGISTRATION UNDER THE SECURITIES ACT AND SUCH OTHER APPLICABLE LAWS.” 

In addition certificates representing the Warrants or the Underlying Shares may contain: 

(i)      any legend required by the laws of the State of California, including any legend
required by the California Department of Corporations; 
 (ii)      any legend
required by the blue sky laws of any other state to the extent such laws are applicable to the sale of such Warrants or Underlying Shares hereunder; and 
  

 14 

 (iii)      a legend regarding affiliate status, if
applicable. 
 (b)     The Company agrees that at such time as such legend is no
longer required under this Section, it will, no later than three business days following the delivery by a Purchaser to the Company or the Company’s transfer agent of a certificate representing Underlying Shares, as applicable, issued with a
restrictive legend, together with such representations and covenants of such Purchaser or such Purchaser’s executing broker as the Company may reasonably require in connection therewith, deliver or cause to be delivered to such Purchaser a
certificate representing such shares that is free from any legend referring to the Securities Act. The Company shall not make any notation on its records or give instructions to any transfer agent of the Company that enlarge the restrictions on
transfer set forth in this Section. Certificates for Underlying Shares subject to legend removal hereunder shall be transmitted by the transfer agent of the Company to the Purchasers by crediting the account of such Purchaser’s prime broker
with the Depository Trust Company (“DTC”). All costs and expenses related to the removal of the legends and the reissuance of any Warrants shall be borne by the Company. 

(c)     The restrictive legend set forth in this section above shall be removed and the Company shall
issue a certificate without such restrictive legend or any other restrictive legend to the holder of the applicable shares upon which it is stamped or issue to such holder by electronic delivery with the applicable balance account at DTC or in
physical certificated shares, if appropriate, if (i) such Underlying Shares are registered for resale under the Securities Act (provided that the Purchaser agrees to only sell such Underlying Shares during such time that such registration
statement is effective and such Purchaser is not aware or has not been notified by the Company that such registration statement has been withdrawn or suspended, and only as permitted by such registration statement); (ii) such Shares are sold or
transferred pursuant to Rule 144 (if the transferor is not an affiliate of the Company); or (iii) such Underlying Shares are eligible for sale without the requirement for the Company to be in compliance with the current public information
required under Rule 144 as to such securities and without volume or manner-of-sale restrictions. Subject to receipt of such representations, and covenants as are contemplated hereby, following the earlier of (x) the effective date of the
Registration Statement or (y) Rule 144 becoming available for the resale of the Underlying Shares, without the requirement for the Company to be in compliance with the current public information required under Rule 144 as to the Underlying
Shares and without volume or manner-of-sale restrictions, the Company shall issue to the Company’s transfer agent the instructions with respect to legend removal consistent with this Section. Any fees (with respect to the transfer agent, the
Company’s counsel or otherwise) associated with the issuance of such opinion or the removal of such legend shall be borne by the Company. 

5.5     Restricted Warrants.   Purchaser understands that the Warrants are
characterized as “restricted securities” under the federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such
Warrants may be resold without registration under the Securities Act only in certain limited circumstances. In this connection, such Purchaser represents that it is familiar with Rule 144, as presently in effect, and understands the resale
limitations imposed thereby and by the Securities Act. 
  

 15 

 5.6     Exercise of Warrants.
  Purchaser agrees to exercise, on or prior to the Closing, such Purchaser’s October 2009 Warrant with respect to that number of shares of Common Stock as set forth on the Exhibit C (the “Exercised Shares”). On or
prior to the Closing, Purchaser shall deliver a notice of warrant exercise in the form of Exhibit A to the October 2009 Warrant and pay the aggregate exercise price for such Exercised Shares by wire transfer of immediately available funds.

 SECTION 6. CONDITIONS TO COMPANY’S OBLIGATIONS AT THE CLOSING. 

The Company’s obligation to complete the sale and issuance of the Warrants and deliver Warrants to each Purchaser,
individually, as set forth in the Schedule of Purchasers at the Closing shall be subject to the following conditions to the extent not waived by the Company: 

6.1     Receipt of Payment.   Subject to Section 7.7, the Company shall have
received payment, by wire transfer of immediately available funds, in the full amount of the purchase price for the Warrant being purchased by such Purchaser at the Closing as set forth in the Schedule of Purchasers. 

6.2     Exercise of October 2009 PIPE Warrants.   Such Purchaser shall have
exercised its October 2009 Warrant pursuant to a Warrant Exercise Notice. The Company shall have received payment from such Purchaser, by wire transfer of immediately available funds, in the full amount of the aggregate exercise price for such
Purchaser’s Exercised Shares. 
 6.3     Representations and Warranties.
  The representations and warranties made by such Purchaser in Section 5 hereof shall be true and correct in all material respects as of, and as if made on, the date of this Agreement and as of the Closing Date. 

6.4     Receipt of Executed Documents.   Such Purchaser shall have executed and
delivered to the Company the Warrant Exercise Notice, the Registration Rights Agreement, the Purchaser Questionnaire, the Selling Stockholder Questionnaire and a waiver of the preemptive rights in Section 8 of the Securities Purchase Agreement.

 6.5     Nasdaq Approval.   The Underlying Shares shall have been
approved for listing on the Nasdaq Capital Market, subject to official notice of issuance. 
 SECTION 7.  CONDITIONS TO
PURCHASERS’ OBLIGATIONS AT THE CLOSING. 
 Each Purchaser’s obligation to accept delivery of the
Warrants and to pay for the Warrants shall be subject to the following conditions to the extent not waived by such Purchaser: 

7.1     Representations and Warranties Correct.   The representations and warranties
made by the Company in Section 4 hereof shall be true and correct in all material respects as of, and as if made on, the date of this Agreement and as of the Closing Date (except that those representations and warranties which address matters
only as of a particular date need only be true and correct as of such date). 
 7.2
    Receipt of Executed Registration Rights Agreement.   The Company shall have executed and delivered to the Purchasers the Registration Rights Agreement. 

 

 16 

 7.3     Legal Opinion.   The Purchasers
shall have received an opinion of Latham & Watkins LLP, special counsel to the Company, substantially in the form set forth in Appendix IV hereto. 

7.4     Certificate.   Each Purchaser shall have received a certificate signed by
the Chief Executive Officer and the Chief Financial or Accounting Officer to the effect that the representations and warranties of the Company in Section 4 hereof are true and correct in all material respects as of, and as if made on, the date
of this Agreement and as of the Closing Date and that the Company has satisfied in all material respects all of the conditions set forth in this Section 7. 

7.5     Good Standing.   The Company is validly existing as a corporation in good
standing under the laws of Delaware. The Company shall have delivered to each Purchaser upon request a certificate, as of a recent date as to the corporate good standing of the Company issued by the Secretary of State of the State of Deleware and
the Secretary of State of California. 
 7.6     Nasdaq Approval.   The
Underlying Shares shall have been approved for listing on the Nasdaq Capital Market, subject to official notice of issuance. 

7.7     Physical Delivery Requirement.   The Company shall have delivered to any
Purchaser whose legal status requires under applicable law such delivery duly executed Warrants (in such denominations as indicated below such Purchaser’s name on the applicable signature page hereto) and in such nominee names as may be
specified by such Purchaser. 
 7.8     Judgments.   No judgment, writ,
order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been
instituted by any governmental authority, enjoining or preventing the consummation of the transactions contemplated hereby. 

7.9     Stop Orders.   No stop order or suspension of trading shall have been
imposed by the Principal Market, the SEC or any other governmental regulatory body with respect to public trading in the Common Stock. 

SECTION 8.  BROKER’S FEES. 

The Company and each Purchaser (severally and not jointly) hereby represent that there are no other brokers or finders
entitled to compensation in connection with the sale of the Securities, and shall indemnify each other for any such fees for which they are responsible. 

SECTION 9.  INDEMNIFICATION. 

9.1     Indemnification by the Company.   The Company agrees to indemnify and hold
harmless each of the Purchasers and each Person, if any, who controls any Purchaser within the meaning of the Securities Act (each, an “Indemnified Party”), against any losses, claims, damages, liabilities or expenses, joint or
several, to which such Indemnified Party may become subject under the Securities Act, the Exchange Act, or any other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such

  

 17 

 
settlement is effected with the written consent of the Company), insofar as such losses, claims, damages, liabilities or expenses (or actions in respect thereof as contemplated below) arise out
of or are based in whole or in part on any inaccuracy in the representations and warranties of the Company contained in this Agreement or any failure of the Company to perform its obligations hereunder, and will reimburse each Indemnified Party for
any legal and other expenses reasonably incurred as such expenses are reasonably incurred by such Indemnified Party in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or
action; provided, however, that the Company will not be liable in any such case to the extent that any such loss, claim, damage, liability or expense arises out of or is based upon (i) the failure of such Indemnified Party to comply with the
covenants and agreements contained in Section 5 above respecting sale of the Warrants (including the Underlying Shares), or (ii) the inaccuracy of any representations made by such Indemnified Party herein. 

9.2     Indemnification by Purchasers.   Each Purchaser shall severally, and not
jointly, indemnify and hold harmless the other Purchasers and the Company, each of its directors, and each Person, if any, who controls the Company within the meaning of the Securities Act, against any losses, claims, damages, liabilities or
expenses to which the Company, each of its directors or each of its controlling Persons may become subject, under the Securities Act, the Exchange Act, or any other federal or state statutory law or regulation, or at common law or otherwise
(including in settlement of any litigation, if such settlement is effected with the written consent of such Purchaser) insofar as such losses, claims, damages, liabilities or expenses (or actions in respect thereof as contemplated below) arise out
of or are based upon (i) any failure by such Purchaser to comply with the covenants and agreements contained in Section 5 above respecting the sale of the Warrants (including the Underlying Shares) unless such failure by such Purchaser is
directly caused by the Company’s failure to provide written notice of a Suspension to such Purchaser or (ii) the inaccuracy of any representation made by such Purchaser herein, in each case to the extent, and will reimburse the Company,
each of its directors, and each of its controlling Persons for any legal and other expense reasonably incurred, as such expenses are reasonably incurred by the Company, each of its directors, and each of its controlling Persons in connection with
investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. No Purchaser shall be liable for the indemnification obligations of any other Purchaser. 

SECTION 10.          ACCESS TO INFORMATION. 

From the date hereof until the Closing, the Company will make reasonably available to the Purchasers’
representatives, consultants and their respective counsels for inspection, such information and documents as the Purchasers reasonably request, and will make available at reasonable times and to a reasonable extent officers and employees of the
Company to discuss the business and affairs of the Company. 
 SECTION 11.          USE OF
PURCHASERS’ NAMES. 
 Except as otherwise required by applicable law or regulation, the Company shall
not use the Purchasers’ names or the name of any of their affiliates in any advertisement, announcement, press release or other similar public communication unless it has received the prior written

  

 18 

 
consent of the applicable Purchaser for the specific use contemplated which consent shall not be unreasonably withheld. 

SECTION 12.          NOTICES. 

All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed
facsimile or electronic mail, or mailed by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of facsimile or electronic mail
transmission, or when so received in the case of mail or courier, and addressed as follows: 
  

	 	(a)	 if to the Company, to: 

Corcept Therapeutics Incorporated 

149 Commonwealth Drive 

Menlo Park, California 94025 

Attention: Caroline Loewy, Chief Financial Officer 

Facsimile: (650) 327-3218 

E-Mail: cloewy@corcept.com 

with a copy to (which copy shall not constitute notice): 

Latham & Watkins LLP 

140 Scott Drive 

Menlo Park, California 94025 

Attention: Alan C. Mendelson 

Facsimile: (650) 463-4693 

E-Mail: alan.mendelson@lw.com 

or to such other person at such other place as the Company shall designate to the Purchasers in writing; and 

(b)      if to the Purchasers, at the address as set forth at the end of this Agreement, or at
such other address or addresses as may have been furnished to the Company in writing. 
 SECTION
13.          MISCELLANEOUS. 
 13.1
    Waivers and Amendments.   Neither this Agreement nor any provision hereof may be changed, waived, discharged, terminated, modified or amended except upon the written consent of the Company and holders of at
least a majority of the Underlying Shares (whether outstanding or represented by the Warrants). 
 13.2
    Headings.   The headings of the various sections of this Agreement have been inserted for convenience of reference only and shall not be deemed to be part of this Agreement. 

 

 19 

 13.3     Severability.   In case any
provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby.

 13.4     Governing Law.   All questions concerning the construction,
validity, enforcement and interpretation of the Transaction Documents shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof (other
than Section 5-1401 of the New York General Obligations Law). Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement and any other Transaction
Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby
irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit,
action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service shall
constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. 

13.5     Counterparts.   This Agreement may be executed in two or more counterparts,
each of which shall constitute an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered to the other
parties. 
 13.6     Successors and Assigns.   Except as otherwise
expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto. 

13.7     Entire Agreement.   This Agreement and other documents delivered pursuant
hereto, including the exhibit and the Schedule of Exceptions, constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and thereof. 

13.8     Payment of Fees and Expenses.   Each of the Company and the Purchasers
shall bear its own expenses and legal fees incurred on its behalf with respect to this Agreement and the transactions contemplated hereby. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the
prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 

 

 20 

 13.9     Interpretative Provisions.
  Whenever the words “include”, “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation”, whether or not they are in fact followed
by those words or words of like import. 
 13.10   Survival.   The representations,
warranties, covenants and agreements made in this Agreement shall survive any investigation made by the Company or the Purchasers and the Closing. 

[signature pages follow] 
  

 21 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to
be executed by their duly authorized representatives as of the day and year first above written. 
  

			
	CORCEPT THERAPEUTICS INCORPORATED
		
	By:	 	 /s/ Caroline Loewy

	Name: Caroline Loewy
	Title: Chief Financial Officer

  

 
 SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 PURCHASERS: 
  

			
	 Ingalls & Snyder Value Partners, L.P.

By: /s/ Thomas O. Boucher Jr.

Name: Thomas O. Boucher Jr.

Title: General Partner
	  	 Robert L.
Gipson
 By: /s/ Robert L. Gipson

Name: Robert L. Gipson

	 Thomas L.
Gipson
 By: /s/ Thomas O. Boucher, Jr., attorney-in-fact

Name: Thomas L. Gipson
	  	 Thomas O. Boucher, Jr.

By: /s/ Thomas O. Boucher, Jr.

Name: Thomas O. Boucher, Jr.

	 Federated
Kaufmann Fund, a portfolio of
 Federated Equity Funds

By: /s/ Hans P. Utsch

Name: Hans P. Utsch

Title: Vice President, Federated Global

Investment Management, as attorney-in-fact
	  	 Federated Kaufmann Fund II, a portfolio
of
 Federated Insurance Series

By: /s/ Aash Shah

Name: Aash Shah

Title: Vice President, Federated Global Investment Management, as attorney-in-fact

	 Federated
Kaufmann Small Cap Fund, a
 portfolio of Federated Equity Funds

By: /s/ Hans P. Utsch

Name: Hans P. Utsch

Title: Vice President, Federated Global

Investment Management, as attorney-in-fact
	  	 American Skandia Trust,
Federated
 Aggressive Growth Portfolio

By: /s/ Aash Shah

Name: Aash Shah

Title: Vice President, Federated Global Investment Management, as attorney-in-fact

	 Longitude
Venture Partners, L.P.
 By: Longitude Capital Partners, LLC

Its: General Partner
 By:
/s/ Patrick Enright
 Name: Patrick Enright

Title: Managing Member
	  	 Longitude Capital Associates, L.P.

 By: Longitude Capital Partners, LLC

Its: General Partner
 By:
/s/ Patrick Enright
 Name: Patrick Enright

Title: Managing Member

	 Sutter Hill
Ventures, a California Limited
 Partnership

By: /s/ G. Leonard Baker, Jr.

Name: G. Leonard Baker, Jr.

Title: Managing Director of the General Partner
	  	 Saunders Holdings,
L.P.
 By: /s/ G. Leonard Baker, Jr.

Name: G. Leonard Baker, Jr.

Title: General Partner

	 Gregory P.
Sands and Sarah J.D. Sands
 as Trustees of Gregory P. and Sarah J.D.

Sands Trust Agreement dated 2/24/99

By: /s/ Robert Yin Under Power of Attorney

Name: Gregory P. Sands

Title: Trustee
	  	 James N. White and Patricia A.
O’Brien
 as Trustees of the White Family Trust

U/A/D 4/3/97
 By: /s/
Robert Yin Under Power of Attorney
 Name: James N. White

Title: Trustee

SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

			
	 Jeffrey W. Bird and Christina R. Bird

as Trustees of Jeffrey W. and Christina

R. Bird Trust Agreement dated 10/31/00

By: /s/ Robert Yin Under Power of Attorney

Name: Jeffrey W. Bird

Title: Trustee
  
	  	
Andrew T. Sheehan and Nicole J. Sheehan

as Trustees of Sheehan 2003 Trust

By: /s/ Robert Yin Under Power of Attorney

Name: Andrew T. Sheehan

Title: Trustee

	
Wells Fargo Bank, N.A. FBO SHV

Profit Sharing Plan FBO David L. Anderson

By: /s/ Vicki M. Bandel

Name: Vicki M. Bandel

Title: Assistant Vice President & Trust Officer
	  	 Wells Fargo Bank, N.A. FBO
SHV
 Profit Sharing Plan FBO G. Leonard Baker, Jr.

By: /s/ Vicki M. Bandel

Name: Vicki M. Bandel

Title: Assistant Vice President & Trust Officer

	
Wells Fargo Bank, N.A. FBO SHV

Profit Sharing Plan FBO William H Younger, Jr.

By: /s/ Vicki M. Bandel

Name: Vicki M. Bandel

Title: Assistant Vice President & Trust Officer
	  	 Wells Fargo Bank, N.A. FBO
SHV
 Profit Sharing Plan FBO Tench Coxe

By: /s/ Vicki M. Bandel

Name: Vicki M. Bandel

Title: Assistant Vice President & Trust Officer

	
Wells Fargo Bank, N.A. FBO SHV

Profit Sharing Plan FBO David E. Sweet

(Rollover)

By: /s/ Vicki M. Bandel

Name: Vicki M. Bandel

Title: Assistant Vice President & Trust Officer
	  	 Wells Fargo Bank, N.A. FBO
SHV
 Profit Sharing Plan FBO Diane J. Naar

By: /s/ Vicki M. Bandel

Name: Vicki M. Bandel

Title: Assistant Vice President & Trust Officer

	
Wells Fargo Bank, N.A. FBO SHV

Profit Sharing Plan FBO Yu-Ying Chen

By: /s/ Vicki M. Bandel

Name: Vicki M. Bandel

Title: Assistant Vice President & Trust Officer
	  	 Wells Fargo Bank, N.A. FBO
SHV
 Profit Sharing Plan FBO Patricia Tom

(Post)

By: /s/ Vicki M. Bandel

Name: Vicki M. Bandel

Title: Assistant Vice President & Trust Officer

	
Wells Fargo Bank, N.A. FBO SHV

Profit Sharing Plan FBO Robert Yin

By: /s/ Vicki M. Bandel

Name: Vicki M. Bandel

Title: Assistant Vice President & Trust Officer
	  	 David L Mahoney &
Winnifred C. Ellis
 1998 Family Trust

By: /s/ David L. Mahoney

Name: David L. Mahoney

Title: Trustee

	
Joseph C. Cook, Jr. and Judith E. Cook, as

Tenants in Common

By: /s/ Joseph C. Cook, Jr.

Name: Joseph C. Cook, Jr.

By: /s/ Judith E. Cook

Name: Judith E. Cook
	  	 Joseph C. Cook, Jr.
IRA
 By: /s/ Joseph C. Cook, Jr.

Name: Joseph C. Cook, Jr.

SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

			
	 Steven D. Singleton

By: /s/ Steven D. Singleton

Name: Steven D. Singleton
	  	
Joseph C. Cook, III

By: /s/ Joseph C. Cook, III

Name: Joseph C. Cook, III

	
Alexander Casdin

By: /s/ Alexander W. Casdin

Name: Alexander W. Casdin
	  	 Byron W.
Smith
 By: /s/ Byron W. Smith

Name: Byron W. Smith

	
Pelmea LP

By: /s/ George H. Conrades

Name: George H. Conrades

Title: Managing Member
	  	 George H. Conrades

 By: /s/ George H. Conrades

Name: George H. Conrades

	
Vaughn D. Bryson

By: /s/ Vaughn D. Bryson

Name: Vaughn D. Bryson
	  	 DeVivo Asset Management Co. LLC

Money Purchase Pension Plan

Fbo Douglas G. DeVivo dtd 1/1/84

	
Steven D. Pruett

By: /s/ Steven D. Pruett

Name: Steven D. Pruett
	  	 By: /s/ Douglas G. DeVivo

 Name: Douglas G. DeVivo

Title: Trustee

	
Black Point Group LP

By: /s/ David E. Shaw

Name: David E. Shaw

Title: General Partner BPG
	  	 David E.
Shaw
 By: /s/ David E. Shaw

Name: David E. Shaw

	
VP Company Investments 2008, LLC

By: /s/ Alan C. Mendelson

Name: Alan C. Mendelson

Title: Member of Management Committee
	  	 Alan C. and Agnes B.
Mendelson Family
 Trust

By: /s/ Alan C. Mendelson

Name: Alan C. Mendelson

Title: Trustee

SIGNATURE PAGES TO 

SECURITIES PURCHASE AGREEMENT 

 EXHIBIT A 

SCHEDULE OF PURCHASERS 
  

						
	Name and Address	  	 Number of
Warrant

 Shares
	 	 	Purchase Price
of Warrants

	
1.      Ingalls & Snyder Value Partners, L.P.
(1)
	  	700,000	   	 	$87,500.00
	
2.      Robert L. Gipson
(1)
	  	350,000	  	 	$43,750.00
	
3.      Thomas L. Gipson
(1)
	  	140,000	  	 	$17,500.00
	
4.      Thomas O. Boucher, Jr.
(1)
	  	33,777	  	 	$4,222.13
	
5.      Federated Kaufmann Fund, a portfolio of Federated Equity Funds
(2)
	  	797,358	  	 	$99,669.75
	
6.      Federated Kaufmann II, a portfolio of Federated Insurance Series
(2)
	  	17,387	  	 	$2,173.38
	
7.      Federated Kaufmann Small Cap Fund, a portfolio of Federated Equity Funds
(2)
	  	121,142	  	 	$15,142.75
	
8.      American Skandia Trust, Federated Aggressive Growth Portfolio
(2)
	  	43,135	  	 	$5,391.88
	
9.      Longitude Venture Partners, L.P.
(3)
	  	839,811	  	 	$104,976.38
	 10.    Longitude
Capital Associates, L.P. (3)
	  	16,833	  	 	$2,104.13
	 11.    Sutter Hill
Ventures, a California Limited Partnership
(4)
	  	307,553	  	 	$38,444.13
	 12.    Saunders
Holdings, L.P. (4)
	  	46,791	  	 	$5,848.88
	 13.    Gregory P.
and Sarah J.D. Sands Trust Agreement dated 2/24/99 (4)

	  	8,437	  	 	$1,054.63
	 14.    The White
Family Trust U/A/D 4/3/97 (4)
	  	8,104	  	 	$1,013.00
	 15.    Jeffrey W.
and Christina R. Bird Trust Agreement dated 10/31/00 (4)

	  	7,298	  	 	$912.25
	 16.    Sheehan 2003
Trust (4)
	  	1,059	  	 	$132.38
	 17.    Wells Fargo
Bank, N.A. FBO SHV Profit Sharing Plan FBO David L. Anderson
(5)
	  	52,301	  	 	$6,537.63
	 18.    Wells Fargo
Bank, N.A. FBO SHV Profit Sharing Plan FBO G. Leonard Baker, Jr.
(5)
	  	98,449	  	 	$12,306.13
	 19.    Wells Fargo
Bank, N.A. FBO SHV Profit Sharing Plan FBO William H Younger, Jr.
(5)
	  	55,493	  	 	$6,936.63
	 20.    Wells Fargo
Bank, N.A. FBO SHV Profit Sharing Plan FBO Tench Coxe (5)

	  	70,867	  	 	$8,858.38
	 21.    Wells Fargo
Bank, N.A. FBO SHV Profit Sharing Plan FBO David E. Sweet (Rollover)
(5)
	  	2,893	  	 	$361.63
	 22.    Wells Fargo
Bank, N.A. FBO SHV Profit Sharing Plan FBO Diane J. Naar
(5)
	  	331	  	 	$41.38
	 23.    Wells Fargo
Bank, N.A. FBO SHV Profit Sharing Plan FBO Yu-Ying Chen
(5)
	  	331	  	 	$41.38
	 24.    Wells Fargo
Bank, N.A. FBO SHV Profit Sharing Plan FBO Patricia Tom (Post)
(5)
	  	1,243	  	 	$155.38
	 25.    Wells Fargo
Bank, N.A. FBO SHV Profit Sharing Plan FBO Robert Yin (5)

	  	165	  	 	$20.63
	 26.    Joseph C.
Cook, Jr. and Judith E. Cook, as Tenants in Common (6)

	  	73,427	  	 	$9,178.38
	 27.    Joseph C.
Cook, Jr. IRA (6)
	  	61,190	  	 	$7,648.75

						
	Name and Address	  	 Number of
Warrant

 Shares
	 	 	Purchase Price
of Warrants

	
28.    Steven D. Singleton
(6)
	  	6,120	   	 	$765.00
	
29.    Joseph C. Cook, III

         2617 Barton Avenue

         Nashville, TN 37212
	  	7,343	  	 	$917.88
	
30.    David L Mahoney & Winnifred C. Ellis

         1998 Family Trust

         Pier 5, The Embarcadero, Suite
102
          San Francisco, CA
94111
	  	48,952	  	 	$6,119.00
	
31.    Alexander Casdin

         131 East
66th Street 10-D

         New York, NY 10065
	  	73,427	  	 	$9,178.38
	
32.    Douglas G DeVivo, Trustee

         DeVivo Asset Management Co. LLC

         Money Purchase Pension Plan

         fbo Douglas G. DeVivo dtd 1/1/84

         40 Laburnum Road

         Atherton, CA 94027
	  	35,000	  	 	$4,375.00
	
33.    George H. Conrades

         344 Beacon Street

         Boston, MA 02116
	  	61,190	  	 	$7,648.75
	
34.    Pelmea LP

         c/o George Conrades

         344 Beacon Street

         Boston, MA 02116
	  	61,188	  	 	$7,648.50
	
35.    Vaughn D. Bryson

         719 Grove Place

         Vero Beach, FL 32963
	  	35,000	  	 	$4,375.00
	
36.    Byron W. Smith

         915 Briarwood Crest

         Nashville, TN 37221
	  	24,476	  	 	$3,059.50
	
37.    David E. Shaw

         542 Blackpoint Rd

         Scarborough ME 04074
	  	24,476	  	 	$3,059.50
	
38.    Black Point Group LP

         100 Fore Street

         Portland ME 04101
	  	24,476	  	 	$3,059.50
	
39.    Steven D. Pruett

         6963 Verde Way

         Naples FL 34108
	  	24,476	  	 	$3,059.50
	
40.    VP Company Investments 2008, LLC

         c/o Russell Player

         555 West Fifth Street, Suite 800

         Los Angeles, CA 90013-1010
	  	2,448	  	 	$306.00
	
41.    Alan C. and Agnes B. Mendelson Family Trust

         c/o Alan C. Mendelson

         76 De Bell Dr

         Atherton, CA 94027
	  	        2,448	  	 	$306.00
	 TOTAL
	  	4,286,395	  	 	$535,799.48

	(1)
	 The address for Ingalls & Snyder Value Partners, L.P. and affiliated individuals is 61 Broadway, New York, NY 10006.

	(2)
	 The address for the Federated Kaufmann funds is 55 Water Street New York, NY 10041. 

	(3)
	 The address for Longitude Capital and related entities is 800 El Camino Real, Suite 220, Menlo Park, California 94025. 

	(4)
	 The address for Sutter Hill Ventures and affiliated entities is 755 Page Mill Road, Suite A-200, Palo Alto, CA 94304. 

	(5)
	 The address for Wells Fargo Bank, NA, is 600 California Street 12th Floor, San Francisco, CA 94108. 

	(6)
	 The address for Joseph C. Cook, Jr., the Joseph C. Cook, Jr. IRA and Steven D. Singleton is Mountain Group Capital, LLC, 1600 Division Street, Suite
580, Nashville, TN 37203. 

 EXHIBIT B 

FORM OF WARRANT 
 See
Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on April 23, 2010. 

 EXHIBIT C 

SCHEDULE OF EXERCISED SHARES 
  

						
	Name and Address	  	
Number of
Exercised

Shares
	 	  	Exercise Price 
of
Exercised Shares
	
         Ingalls & Snyder Value Partners, L.P.
(1)
	  	700,000	   	  	$1,162,000.00
	
         Robert L. Gipson
(1)
	  	350,000	  	  	$581,000.00
	
         Thomas L. Gipson
(1)
	  	140,000	  	  	$232,400.00
	
         Thomas O. Boucher, Jr.
(1)
	  	33,777	  	  	$56,069.82
	
         Federated Kaufmann Fund, a portfolio of Federated Equity Funds
(2)
	  	797,358	  	  	$1,323,614.28
	
         Federated Kaufmann II, a portfolio of Federated Insurance Series
(2)
	  	17,387	  	  	$28,862.42
	
         Federated Kaufmann Small Cap Fund, a portfolio of Federated Equity Funds
(2)
	  	121,142	  	  	$201,095.72
	
         American Skandia Trust, Federated Aggressive Growth Portfolio
(2)
	  	43,135	  	  	$71,604.10
	
         Longitude Venture Partners, L.P.
(3)
	  	839,811	  	  	$1,394,086.26
	
         Longitude Capital Associates, L.P.
(3)
	  	16,833	  	  	$27,942.78
	
         Sutter Hill Ventures, a California Limited Partnership
(4)
	  	307,553	  	  	$510,537.98
	
         Saunders Holdings, L.P.
(4)
	  	46,791	  	  	$77,673.06
	
         Gregory P. and Sarah J.D. Sands Trust Agreement dated 2/24/99
(4)
	  	8,437	  	  	$14,005.42
	
         The White Family Trust U/A/D 4/3/97
(4)
	  	8,104	  	  	$13,452.64
	
         Jeffrey W. and Christina R. Bird Trust Agreement dated 10/31/00
(4)
	  	7,298	  	  	$12,114.68
	
         Sheehan 2003 Trust
(4)
	  	1,059	  	  	$1,757.94
	
         Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO David L. Anderson
(5)
	  	52,301	  	  	$86,819.66
	
         Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO G. Leonard Baker, Jr.
(5)
	  	98,449	  	  	$163,425.34
	
         Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO William H Younger, Jr.
(5)
	  	55,493	  	  	$92,118.38
	
         Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Tench Coxe
(5)
	  	70,867	  	  	$117,639.22
	
         Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO David E. Sweet
(Rollover) (5)
	  	2,893	  	  	$4,802.38
	
         Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Diane J. Naar
(5)
	  	331	  	  	$549.46
	
         Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Yu-Ying Chen
(5)
	  	331	  	  	$549.46
	
         Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Patricia Tom (Post)
(5)
	  	1,243	  	  	$2,063.38
	
         Wells Fargo Bank, N.A. FBO SHV Profit Sharing Plan FBO Robert Yin
(5)
	  	165	  	  	$273.90
	
         Joseph C. Cook, Jr. and Judith E. Cook, as Tenants in Common
(6)
	  	73,427	  	  	$121,888.82
	
         Joseph C. Cook, Jr. IRA
(6)
	  	61,190	  	  	$101,575.40
	
         Steven D. Singleton
(6)
	  	6,120	  	  	$10,159.20
	
         Joseph C. Cook, III
	  		 	  	 
	
         2617 Barton Avenue
	  		 	  	 
	
         Nashville, TN 37212
	  	7,343	  	  	$12,189.38

						
	Name and Address	  	
Number of
Exercised

Shares
	 	 	Exercise Price 
of
Exercised Shares
	
         David L Mahoney & Winnifred C. Ellis
1998 Family Trust
          Pier 5, The
Embarcadero, Suite 102
          San
Francisco, CA 94111
	  	48,952	   	 	$81,260.32
	
         Alexander Casdin

         131 East
66th Street 10-D

         New York, NY 10065
	  	73,427	  	 	$121,888.82
	
         Douglas G DeVivo, Trustee

         DeVivo Asset Management Co. LLC

         Money Purchase Pension Plan

         fbo Douglas G. DeVivo dtd 1/1/84

         40 Laburnum Road

         Atherton, CA 94027
	  	35,000	  	 	$58,100.00
	
         George H. Conrades

         344 Beacon Street

         Boston, MA 02116
	  	61,190	  	 	$101,575.40
	
         Pelmea LP

         c/o George Conrades

         344 Beacon Street

         Boston, MA 02116
	  	61,188	  	 	$101,572.08
	
         Vaughn D. Bryson

         719 Grove Place

         Vero Beach, FL 32963
	  	35,000	  	 	$58,100.00
	
         Byron W. Smith

         915 Briarwood Crest

         Nashville, TN 37221
	  	24,476	  	 	$40,630.16
	
         David E. Shaw

         542 Blackpoint Rd

         Scarborough ME 04074
	  	24,476	  	 	$40,630.16
	
         Black Point Group LP

         100 Fore Street

         Portland ME 04101
	  	24,476	  	 	$40,630.16
	
         Steven D. Pruett

         6963 Verde Way

         Naples FL 34108
	  	24,476	  	 	$40,630.16
	
         VP Company Investments 2008, LLC

         c/o Russell Player

         555 West Fifth Street, Suite 800

         Los Angeles, CA 90013-1010
	  	2,448	  	 	$4,063.68
	
         Alan C. and Agnes B. Mendelson Family Trust

          c/o Alan C.
Mendelson
          76 De Bell
Dr
          Atherton, CA
94027
	  	        2,448	  	 	$4,063.68
	
TOTAL
	  	4,286,395	  	 	$7,115,415.70

 

	 	(1)
	 The address for Ingalls & Snyder Value Partners, L.P. and affiliated individuals is 61 Broadway, New York, NY 10006.

	 	(2)
	 The address for the Federated Kaufmann funds is 55 Water Street New York, NY 10041. 

	 	(3)
	 The address for Longitude Capital and related entities is 800 El Camino Real, Suite 220, Menlo Park, California 94025. 

	 	(4)
	 The address for Sutter Hill Ventures and affiliated entities is 755 Page Mill Road, Suite A-200, Palo Alto, CA 94304. 

	 	(5)
	 The address for Wells Fargo Bank, NA, is 600 California Street 12th Floor, San Francisco, CA 94108. 

	 	(6)
	 The address for Joseph C. Cook, Jr., the Joseph C. Cook, Jr. IRA and Steven D. Singleton is Mountain Group Capital, LLC, 1600 Division Street, Suite
580, Nashville, TN 37203. 

 APPENDIX I 

FORM OF PURCHASER QUESTIONNAIRE 

CORCEPT THERAPEUTICS INCORPORATED 

PURCHASER QUESTIONNAIRE 

(ALL INFORMATION WILL BE TREATED CONFIDENTIALLY) 
  

			
	 To:
	 	 Corcept Therapeutics Incorporated

		 	 149 Commonwealth Drive

		 	 Menlo Park, CA 94025

This Purchaser Questionnaire (“Questionnaire”) must be completed by each potential investor in connection with
the offer and sale of warrants (“Warrants”) to purchase shares of the Company’s Common Stock, par value $0.001 per share (the “Common Stock”), pursuant to the Warrant Purchase Agreement by and among Corcept Therapeutics
Incorporated (the “Company”) and those persons or entities listed as purchasers on Exhibit A thereto (the “Purchasers”). Warrants are being offered and sold by the Company without registration under the Securities Act of 1933, as
amended (the “Act”), and the securities laws of certain states, in reliance on the exemptions contained in Section 4(2) of the Act and on Regulation D promulgated thereunder and in reliance on similar exemptions under applicable state
laws. The Company must determine that a potential investor meets certain suitability requirements before offering or selling Warrants to such investor. The purpose of this Questionnaire is to assure the Company that each investor will meet the
applicable suitability requirements. The information supplied by you will be used in determining whether you meet such criteria, and reliance upon the private offering exemption from registration is based in part on the information herein supplied.

 This Questionnaire does not constitute an offer to sell or a solicitation of an offer to buy any security.
Your answers will be kept strictly confidential. However, by signing this Questionnaire you will be authorizing the Company to provide a completed copy of this Questionnaire to such parties as the Company deems appropriate in order to ensure that
the offer and sale of Warrants will not result in a violation of the Act or the securities laws of any state and that you otherwise satisfy the suitability standards applicable to purchasers of Warrants. All potential investors must answer all
applicable questions and complete, date and sign this Questionnaire. Please print or type your responses and attach additional sheets of paper if necessary to complete your answers to any item. 

 

	A.	 BACKGROUND INFORMATION 

  

			
	 Name:
	  	 

			
		
	Business Address:	  	 
	 (Number and Street)

 

			
	 	  	 
	 (City)
	  	(State)                          
                  (Zip Code)
	Telephone Number:	  	 
	E-Mail Address:	  	 
	Residence Address:	  	 
	 (Number and Street)

 

	 
	 (City)
	  	(State)                          
                  (Zip Code)
	Telephone Number:	  	 

			
	If an individual:	  	
	
Age:                       
              Citizenship:                
              Where registered to
vote:                                        
         

	If a corporation, partnership, limited liability company, trust or other entity:
	Type of
entity:                                        
                                         
                                         
                                         
                                         
                         
	State of formation:                     	  	 Date of formation:             

	Social Security or Taxpayer Identification No.:	  	 

 Send all correspondence to (check one):
             Residence Address                         
Business Address 
 Current ownership of securities of the Company: 

                   
          shares of common stock, par value $0.001 per share (the “Common Stock”) 

options to purchase
                         shares of Common Stock 

warrants to purchase
                         shares of Common Stock 

 

	B.	 STATUS AS ACCREDITED INVESTOR 

The undersigned is an “accredited investor” as such term is defined in Regulation D under the Act, as at the time of the
sale of Warrants the undersigned falls within one or more of the following categories (Please initial one or more, as
applicable):1 

                (1)     
   a bank as defined in Section 3(a)(2) of the Act, or a savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity; a broker or dealer
registered pursuant to Section 15 of the Securities Exchange Act of 1934; an insurance company as defined in Section 2(13) of the Act; an investment company registered under the Investment Corporation Act of 1940 or a business development
company as defined in Section 2(a)(48) of that Act; a Small Business Investment Corporation licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958; a plan
established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions for the benefit of its employees, if such plan has total assets in excess of $5,000,000; an employee benefit
plan within the meaning of the Employee Retirement Income Security Act of 1974 if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such Act, which is either a bank, savings and loan association, insurance
company, or registered investment adviser, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with the investment decisions made solely by persons that are accredited investors; 

                (2)     
   a private business development company as defined in Section 202(a)(22) of the Investment Adviser Act of 1940; 

                (3)     
   an organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring Warrants
offered, with total assets in excess of $5,000,000; 

                (4)  
      a natural person whose individual net
worth1, or joint net
worth1 with that person’s spouse, at the time of such
person’s purchase of Warrants exceeds $1,000,000; 

                (5)     
   a natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with that person’s spouse in excess of $300,000 in each of those years and has a reasonable expectation of
reaching the same income level in the current year; 

                (6)     
   a trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring Warrants offered, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) of Regulation D; and

                (7)     
   an entity in which all of the equity owners are accredited investors (as defined above). 
  

	C.	 REPRESENTATIONS 

The undersigned hereby represents and warrants to the Company as follows: 

 
  

1
 As used in this Questionnaire, the term “net worth” means the excess of total assets over total liabilities. In computing net worth for the purpose of subsection (4), the
principal residence of the investor must be valued at cost, including cost of improvements, or at recently appraised value by an institutional lender making a secured loan, net of encumbrances. In determining income, the investor should add to the
investor’s adjusted gross income any amounts attributable to tax exempt income received, losses claimed as a limited partner in any limited partnership, deductions claimed for depiction, contributions to an IRA or KEOGH retirement plan, alimony
payments, and any amount by which income from long-term capital gains has been reduced in arriving at adjusted gross income. 

	1.	 Any purchase of Warrants would be solely for the account of the undersigned and not for the account of any other person or with a view to any
resale, fractionalization, division, or distribution thereof. 

	2.	 The information contained herein is complete and accurate and may be relied upon by the Company, and the undersigned will notify the Company
immediately of any material change in any of such information occurring prior to the closing, if any, with respect to the purchase of Warrants by the undersigned or any co-purchaser. 

	3.	 There are no suits, pending litigation, or claims against the undersigned that could materially affect the net worth of the undersigned as reported
in this Questionnaire. 

 IN WITNESS WHEREOF, the undersigned has executed this Questionnaire this
         day of                     , 2010, and declares under oath that it is truthful and
correct. 
  

			
	 
	 Print Name

	 By:
	 	 
		 	 Signature

		
	 Title:
	 	 
		 	 (required for any purchaser that is a corporation, partnership, trust or other entity)

 APPENDIX II 

FORM OF SELLING STOCKHOLDER NOTICE AND QUESTIONNAIRE 

	
	
	  
	Name of Selling Stockholder (please print)

CORCEPT THERAPEUTICS INCORPORATED 

QUESTIONNAIRE FOR SELLING STOCKHOLDERS 

IMPORTANT: IMMEDIATE ATTENTION REQUIRED 

This Questionnaire is being furnished to all persons or entities (the “Purchasers”) electing to purchase
warrants (“Warrants”) to purchase shares of Common Stock (“Common Stock”) of Corcept Therapeutics Incorporated (the “Company”) pursuant to the Warrant Purchase Agreement by and among the Company and the Purchasers (the
“Purchase Agreement”) to which this Questionnaire is an Appendix. This Questionnaire relates to certain information required to be disclosed in the Registration Statement on Form S-3 being prepared by the Company for filing with the
United States Securities and Exchange Commission (the “SEC”) pursuant to the Registration Rights Agreement entered into by the Company and the Purchasers (the “Registration Rights Agreement”) in connection with the Purchase
Agreement. The Company must receive a completed Questionnaire from each Purchaser in order to include such Purchaser’s shares of Common Stock issuable upon exercise of Warrants in the Registration Statement. 

The furnishing of accurate and complete responses to the questions posed in this Questionnaire is an extremely important
part of the registration process. The inclusion of inaccurate or incomplete disclosures in the Registration Statement can result in potential liabilities, both civil and criminal, to the Company and to the individuals who furnish the information.
Accordingly, Purchasers are advised to consult their own securities law counsel regarding the consequences of being named or not being named as a selling securityholder in the Registration Statement and related prospectus. 

PLEASE GIVE A RESPONSE TO EVERY QUESTION, indicating “None” or “Not Applicable” where
appropriate. Please complete, sign, and return one copy of this Questionnaire by facsimile, email or overnight courier as soon as possible. 

Latham & Watkins 

505 Montgomery St., Suite 2000 

San Francisco, CA 94109 

Attn:
                         

Fax:
                         

Email:
                         

Unless stated otherwise, answers should be given as of the date you complete this Questionnaire. However, it is your responsibility to
inform us of any changes that may occur to your situation. If there is any situation about which you have any doubt, or if you are uncertain as to the meaning of any terms used in this Questionnaire, please contact
                                . 

 PART I - STOCK OWNERSHIP 

Item 1. Beneficial Ownership. 

a. Deemed Beneficial Ownership. Please state the amount of securities of the Company you own on April 15,
2010. (If none, please so state in each case.) 
  

					
	 Amount Beneficially
Owned1
	  	 Number of Shares of
Common Stock Owned
	  	  
	 Please state the number of shares owned by you or by family members, trusts and other organizations with which you have a relationship, and any other shares of
which you may be deemed to be the “beneficial
owner”1:
	  		  	
	 Total Shares:
	  	 	  	
			
	 Of such shares:
	  		  	
			
	         Shares as to which you have sole
	  		  	
	         voting power:
	  	 	  	
			
	         Shares as to which you have shared
	  		  	
	         voting power:
	  	 	  	
			
	         Shares as to which you have sole
	  		  	
	         investment power:
	  	 	  	
			
	         Shares as to which you have shared
	  		  	
	         investment power:
	  	 	  	
			
	         Shares which you will have a right to
	  		  	
	         acquire before June 14, 2010
	  		  	
	         through the exercise of
	  		  	
	         options, warrants or otherwise:
	  	 	  	

 Do you have any present plans to exercise options or otherwise acquire, dispose of or to transfer
shares of Common Stock of the Company between the date you complete this Questionnaire and the date which is 60 days after the date in which the Registration Statement is filed? 

                       
                             Answer: 

If so, please describe. 

b.             Pledged Securities. If any of such securities have been
pledged or otherwise deposited as collateral or are the subject matter of any voting trust or other similar agreement or of any contract providing for the sale or other disposition of such securities, please give the details thereof. 

                       
                             Answer: 

c.             Disclaimer of Beneficial Ownership.
Do you wish to disclaim beneficial ownership1 of any of
the shares reported in response to Item 1(a)? 

                         
                           Answer: 

If the answer is “Yes”, please furnish the following information with respect to the person
or persons who should be shown as the beneficial owner(s)1
of the shares in question. 
  

					
	 Name and Address of
Actual Beneficial Owner
	  	 Relationship of
Such Person To You
	  	 Number of Shares
Beneficially Owned

		  		  	

 d.         Shared Voting or Investment Power over
Securities. Will any person be deemed to have beneficial ownership over any of the Securities purchased by you pursuant to the Purchase Agreement? 

                         
                   Answer: 

If the answer is “Yes”, please furnish the following information with respect to the person
or persons who should be shown as the beneficial owner(s)1
of the Securities in question. 
  

					
	 Name and Address of
Beneficial Owner
	  	 Relationship of
Such Person To You
	  	 Number of Shares
Beneficially Owned

Item 2. Major Shareholders. Please state below the names of persons or groups known by you to own
beneficially1 more than 5% of the Company’s Common
Stock. 

                         
                   Answer: 

Item 3. Change of Control. Do you know of any contractual arrangements, including any pledge of securities of the
Company, the operation of which may at a subsequent date result in a change of control of the Company? 

                         
                   Answer: 

Item 4. Relationship with the Company. Please state the nature of any position, office or other material relationship
you have, or have had since April 1, 2007, with the Company or its affiliates. 
  

			
	 Name
	  	Nature of
Relationship

Item 5 Broker-Dealer Status Is the Purchaser a broker-dealer registered pursuant to Section 15 of the Exchange Act? 

 ̈ Yes. 

 ̈ No. 

Note that the Company will be required to identify any registered broker-dealer as an underwriter in the prospectus. 

If so, please answer the remaining questions in this section. 

a.        If the Purchaser is a registered broker-dealer, please indicate whether the Purchaser
purchased its Common Stock for investment or acquire them as transaction-based compensation for investment banking or similar services. 

                         
                   Answer: 
 Note: if the
Purchaser is a registered broker-dealer and received its Common Stock other than as transaction-based compensation, the Company is required to identify the Purchaser as an underwriter in the Registration Statement and related Prospectus.

 b.         Is the Purchaser an affiliate of a registered broker-dealer? For
purposes of this Question, an “affiliate” of a specified person or entity means a person or entity that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, the person
or entity specified. 
  ̈ Yes. 

 ̈ No. 

If so, please answer the remaining questions in this section. 

i.       Please describe the affiliation between the Purchaser and any registered
broker-dealers: 
 ii.       If the Common Stock were received by the Purchaser
other than in the ordinary course of business, please describe the circumstances: 

 iii.       If the Purchaser, at the time of
its receipt of Common Stock, has had any agreements or understandings, directly or indirectly, with any person to distribute the Common Stock, please describe such agreements or understandings: 

Note that if the Purchaser is an affiliate of a broker-dealer and did not receive its Common Stock in the ordinary course of business or at the time
of receipt had any agreements or understandings, directly or indirectly, to distribute the securities, the Company must identify the Purchaser as an underwriter in the Prospectus. 

Item 6 Nature of Beneficial Holding The purpose of this question is to identify the ultimate natural person(s) or
publicly held entity that exercise(s) sole or shared voting or dispositive power over the Registrable Securities. 
 a.
    Is the Purchaser a natural person? 
  ̈
Yes. 
  ̈ No. 

b.     Is the Purchaser required to file, or is it a wholly owned subsidiary of a company that is required to file,
periodic and other reports (for example, form 10-K, 10-Q, 8-K) with the Securities and Exchange Commission pursuant to Section 13(a) or 15(d) of the Exchange Act? 

 ̈ Yes. 

 ̈ No. 

c.     Is the Purchaser an investment company, or a subsidiary of an investment company, registered under the
Investment Company Act of 1940, as amended? 
  ̈ Yes. 

 ̈ No. 

If a subsidiary, please identify the publicly held parent entity: 

d.     If you answered “no” to questions (a), (b) and (c) above, please identify the controlling
person(s) of the Purchaser (the “Controlling Entity”). If the Controlling Entity is not a natural person or a publicly held entity, please identify each controlling person(s) of such Controlling Entity. This process should be repeated
until you reach natural persons or a publicly held entity that exercises sole or shared voting or dispositive power over the Registrable Securities: 

***PLEASE NOTE THAT THE SECURITIES AND EXCHANGE COMMISSION REQUIRES THAT THESE NATURAL PERSONS BE NAMED IN THE PROSPECTUS*** 

PART II - CERTAIN TRANSACTIONS 

Item 7. Transactions with the Company. If you, any of your
associates2, or any member of your immediate
family3 had or will have any direct or indirect material
interest in any transactions4 or series of transactions to
which the Company or any of its subsidiaries was a party at any time since April 1, 2007, or in any currently proposed transactions or series of transactions in which the Company or any of its subsidiaries will be a party, in which the amount
involved exceeds $120,000, please specify (a) the names of the parties to the transaction(s) and their relationship to you, (b) the nature of the interest in the transaction, (c) the amount involved in the transaction and (d) the
amount of the interest in the transaction. If the answer is “none”, please so state. 

                         
                   Answer: 

Item 8. Third Party Payments. Please describe any compensation paid to you by a third party pursuant to any arrangement
between the Company and any such third party. 

                         
                   Answer: 

 PART III – PLAN OF DISTRIBUTION 

The selling stockholders and any of their pledgees, donees, transferees, assignees or other successors-in-interest may,
from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions.
These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. The selling stockholders may use
one or more of the following methods when disposing of the shares or interests therein: 
  

	 	•	 	 ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; 

	 	•	 	 block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal to
facilitate the transaction; 

	 	•	 	 through brokers, dealers or underwriters that may act solely as agents; 

	 	•	 	 purchases by a broker-dealer as principal and resale by the broker-dealer for its account; 

	 	•	 	 an exchange distribution in accordance with the rules of the applicable exchange; 

	 	•	 	 privately negotiated transactions; 

	 	•	 	 short sales; 

	 	•	 	 through the writing or settlement of options or other hedging transactions entered into after the effective date of the registration statement of
which this prospectus is a part, whether through an options exchange or otherwise; 

	 	•	 	 broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;

	 	•	 	 a combination of any such methods of disposition; and 

	 	•	 	 any other method permitted pursuant to applicable law. 

The selling stockholders may also sell shares under Rule 144 under the Securities Act of 1933, as amended, or Securities
Act, if available, rather than under this prospectus. 
 Broker-dealers engaged by the selling stockholders may
arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling stockholders (or, if any broker-dealer acts as agent for the purchaser of shares, from the purchaser) in amounts to be
negotiated. The selling stockholders do not expect these commissions and discounts to exceed what is customary in the types of transactions involved. 

The selling stockholders may from time to time pledge or grant a security interest in some or all of the shares of common
stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell shares of common stock from time to time under this prospectus, or under a supplement or amendment to this
prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus.

 Upon being notified in writing by a selling stockholder that any material arrangement has been entered into
with a broker-dealer for the sale of common stock through a block trade, special offering, exchange distribution or secondary distribution or a purchase by a broker or dealer, we will file a supplement to this prospectus, if required, pursuant to
Rule 424(b) under the Securities Act, disclosing (i) the name of each such selling stockholder and of the participating broker-dealer(s), (ii) the number of shares involved, (iii) the price at which such shares of common stock were
sold, (iv) the commissions paid or discounts or concessions allowed to such broker-dealer(s), where applicable, (v) that such broker-dealer(s) did not conduct any investigation to verify the information set out or incorporated by reference
in this prospectus, and (vi) other facts material to the transaction. In addition, upon being notified in writing by a selling stockholder that a donee or pledge intends to sell more than 500 shares of common stock, we will file a supplement to
this prospectus if then required in accordance with applicable securities law. 

 The selling stockholders also may transfer the shares of common stock in
other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. 

In connection with the sale of the shares of common stock or interests in shares of common stock, the selling
stockholders may enter into hedging transactions after the effective date of the registration statement of which this prospectus is a part with broker-dealers or other financial institutions, which may in turn engage in short sales of the common
stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of common stock short after the effective date of the registration statement of which this prospectus is a part and deliver these securities to
close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions after the effective date of the registration
statement of which this prospectus is a part with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered
by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). 

The selling stockholders and any broker-dealers or agents that are involved in selling the shares may be deemed to be
“underwriters” within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them may be deemed to
be underwriting commissions or discounts under the Securities Act. The maximum commission or discount to be received by any member of the Financial Industry Regulatory Authority (FINRA) or independent broker-dealer will not be greater than 8% of the
initial gross proceeds from the sale of any security being sold. 
 We have advised the selling stockholders
that they are required to comply with Regulation M promulgated under the Securities and Exchange Act during such time as they may be engaged in a distribution of the shares. The foregoing may affect the marketability of the common stock. 

The aggregate proceeds to the selling securityholders from the sale of the common stock offered by them will be the
purchase price of the common stock less discounts or commissions, if any. Each of the selling securityholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of
common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. 

We are required to pay all fees and expenses incident to the registration of the shares. We have agreed to indemnify the
selling stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act or otherwise. 

We have agreed with the selling stockholders to keep the registration statement of which this prospectus constitutes a
part effective until the earlier of (a) the date that is three years after the Closing Date (as defined in the Purchase Agreement) and (b) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in
accordance with the registration statement of which this prospectus forms a part or pursuant to Rule 144 of the Securities Act. 

*          *          * 

The undersigned has reviewed the Plan of Distribution set forth above and does not have a present intention of effecting a sale in a
manner not described therein. 

                         
   ______               Agree              ____
                Disagree 
 (If left blank, response will be
deemed to be “Agree”.) 
 The undersigned hereby represents that the undersigned understands, pursuant to the
Securities Act Sections Compliance and Disclosure Interpretations Section 239.10, a copy of which is attached hereto as Exhibit 1, that the undersigned may 

 
not make any short sale of the Common Stock prior to the effectiveness of the Registration Statement, and further covenants to the Company that the undersigned will not engage in any short sales
of such stock to be registered under the Registration Statement prior to its effectiveness. 

 SIGNATURE 

The undersigned understands that the Company anticipates filing the Registration Statement within the time frame set forth in the
Registration Rights Agreement. If at any time any of the information set forth in my responses to this Questionnaire has materially changed due to passage of time, or any development occurs which requires a change in any of my answers, or has for
any other reason become incorrect, the undersigned agrees to furnish as soon as practicable to the individual to whom a copy of this Questionnaire is to be sent, as indicated and at the address shown on the first page hereof, any necessary or
appropriate correcting information. Otherwise, the Company is to understand that the above information continues to be, to the best of my knowledge, information and belief, complete and correct. 

Upon any sale of Common Stock pursuant to the Registration Statement, the undersigned hereby agrees to deliver to the Company and to
Continental Stock Transfer & Trust Company, as transfer agent, the Certificate of Subsequent Sale set forth in Exhibit I hereto. 

The undersigned understands that the information that the undersigned is furnishing to the Company herein will be used by
the Company in the preparation of the Registration Statement. 
  

			
		
		  	 Name of Purchaser: _____________________________

		
	 Date:                     , 2010
	  	 Signature: _____________________________________

		
		  	 Print Name: ___________________________________

		
		  	 Title (if applicable): _____________________________

		
		  	 Address: ______________________________________

		
		  	                 ______________________________________

		
		  	 Street
  

______________________________________________

		  	 City
                                State
                    Zip Code

		
		  	 ______________________________________________

		  	 Telephone Number

		
		  	 ______________________________________________

		  	 Facsimile Number

 FOOTNOTES 

	1.	 Beneficial Ownership. You are the beneficial owner of a security, as defined in Rule 13d-3 under the Securities Exchange Act of 1934
(the “Exchange Act”), if you, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise have or share: (1) voting power, which includes the power to vote, or to direct the voting of, such
security, and/or (2) investment power, which includes the power to dispose, or to direct the disposition of, such security. You are also the beneficial owner of a security if you, directly or indirectly, create or use a trust, proxy, power of
attorney, pooling arrangement or any other contract, arrangement, or device with the purpose or effect of divesting yourself of beneficial ownership of a security or preventing the vesting of such beneficial ownership. 

You are deemed to be the beneficial owner of a security if you have the right to acquire beneficial ownership of such
security at any time within 60 days including, but not limited to, any right to acquire such security (a) through the exercise of any option, warrant or right, (b) through the conversion of a security, or (c) pursuant to the
automatic termination of, or the power to revoke a trust, discretionary account, or similar arrangement. Ordinarily, shares held in the name of your spouse or minor child should be considered as beneficially owned by you absent special circumstances
to indicate that you do not have, as a practical matter, voting power or investment power over such shares. Similarly, absent countervailing facts, securities held in the name of relatives who share your home are to be reported as being beneficially
owned by you. In addition, securities held for your benefit in the name of others, such as nominees, trustees and other fiduciaries, securities held by a partnership of which you are a partner, and securities held by a corporation controlled by you
should be regarded as beneficially owned by you. This definition of beneficial ownership is very broad; therefore, even through you may not actually have or share voting or investment power with respect to securities owned by persons in your family
or living in your home, you should include such shares in your beneficial ownership disclosure and may then disclaim beneficial ownership of such securities. 

	2.	 Associate. The term “associate”, as defined in Rule 14a-1 under the Exchange Act, means (a) any corporation or
organization (other than the Company or any of its majority owned subsidiaries) of which you are an officer or partner or are, directly or indirectly, the beneficial owner of 10% or more of any class of equity securities, (b) any trust or other
estate in which you have a substantial beneficial interest or as to which you serve as trustee or in a similar capacity, and (c) your spouse, or any relative of yours or relative of your spouse living in your home or who is a director or
officer of the Company or of any subsidiary. The term “relative of yours” as used in this Questionnaire refers to any relative or spouse of yours, or any relative of such spouse, who has the same home as you or who is a director or officer
of any subsidiary of the Company. 

 Please identify your associate referred to in your answer
and indicate your relationship. 

	3.	 Immediate Family. The members of your “immediate family” are deemed to include the following: your spouse; your parents; your
children; your siblings; your mother-in-law or father-in-law; your sons and daughters-in-law; and your brothers and sisters-in-law. 

	4.	 Transactions. The term “transaction” is to be understood in its broadest sense, and includes the direct or indirect receipt of
anything of value. Please note that indirect as well as direct material interests in transactions are to be disclosed. Transactions in which you would have a direct interest would include your purchasing or leasing anything (stock in a business
acquired by the Company, office space, plants, Company apartments, computers, raw materials, finished goods, etc.) from or selling or leasing anything to, or borrowing or lending cash or other property from or to, the Company, or any subsidiary.

 Exhibit 1 

Securities Act Sections Compliance and Disclosure Interpretations Section 239.10: 

“An issuer filed a Form S-3 registration statement for a secondary offering of common stock which is not yet
effective. One of the selling shareholders wanted to do a short sale of common stock “against the box” and cover the short sale with registered shares after the effective date. The issuer was advised that the short sale could not be made
before the registration statement becomes effective, because the shares underlying the short sale are deemed to be sold at the time such sale is made. There would, therefore, be a violation of Section 5 if the shares were effectively sold prior
to the effective date.” 

 Exhibit I 

CERTIFICATE OF SUBSEQUENT SALE 

Continental Stock Transfer & Trust Company 

17 Battery Place 
 New York, NY 10004 

	 	RE:	 Sale of Shares of Common Stock of Corcept Therapeutics Incorporated. (the “Company”) 

	 	  	 pursuant to the Company’s Prospectus dated
                    ,        (the “Prospectus”) 

Dear Sir/Madam: 
 The
undersigned hereby certifies, in connection with the sale of shares of Common Stock of the Company included in the table of Selling Stockholders in the Prospectus, that the undersigned has sold the shares pursuant to the Prospectus and in a manner
described under the caption “Plan of Distribution” in the Prospectus and that such sale complies with all securities laws applicable to the undersigned, including, without limitation, the Prospectus delivery requirements of the Securities
Act of 1933, as amended. 
 Selling Stockholder (the beneficial owner): _____________________________________________________________________

 Record Holder (e.g., if held in name of nominee): ________________________________________________________________ 

Restricted Stock Certificate No.(s): __________________________________________________________________________ 

Number of Shares Sold:____________________________________________________________________________________ 

Date of Sale: ___________________________________________________________________________________________ 

In the event that you receive a stock certificate(s) representing more shares of Common Stock than have been sold by the undersigned, then
you should return to the undersigned a newly issued certificate for such excess shares in the name of the Record Holder and BEARING A RESTRICTIVE LEGEND. Further, you should place a stop transfer on your records with regard to such
certificate. Notwithstanding the foregoing, in the event that the undersigned executes and delivers to you and to the Company the certification set forth on Annex I, upon instructions from the Company, you should return to the undersigned a newly
issued certificate for such excess shares of Common Stock in the name of the Record Holder without any restrictive legend. In addition, no subsequent certification will be required to be delivered to you by the undersigned provided that the
representations and warranties set forth on Annex I have been delivered to you and continue to be accurate. 
  

									
		 		 	Very truly yours,
					
	Dated:	 	____	 		 	By:	 	 
					
		 		 		 	Print Name:	 	 
					
		 		 		 	Title:	 	 

	cc:	   Corcept Therapeutics Incorporated 

	    	   149 Commonwealth Drive 

	    	   Menlo Park, CA 94025 

	    	   Attn: Chief Financial Officer 

 Annex I 

In connection with any excess shares to be returned to the Selling Stockholder upon a sale of shares of Common Stock of Corcept
Therapeutics Incorporated (the “Company”) included in the table of Selling Stockholders in the Prospectus, the undersigned hereby certifies to the Company and Continental Stock Transfer & Trust Company, that: 

1.         In connection with the sale by the undersigned stockholder of any of the shares of
Common Stock, the undersigned stockholder will deliver a copy of the Prospectus included in the Registration Statement to the purchaser directly or through the undersigned stockholder’s broker-dealer in compliance with the requirements of the
Securities Act of 1933 and the Securities Exchange Act of 1934. 
 2.         Any such
sale will be made only in the manner described under “Plan of Distribution” in the Prospectus. 
 3.
        The undersigned stockholder will only sell the shares of Common Stock while the Registration Statement is effective, unless another exemption from registration is available. 

4.         The Company and its attorneys may rely on this letter to the same extent as if it were
addressed to them. 
 5.         The undersigned stockholder agrees to notify you
immediately of any development or occurrence which to his, her or its knowledge would render any of the foregoing representations and agreements inaccurate. 

All terms not defined herein are as defined in the Warrant Purchase Agreement made as of April 21, 2010 among the Company and the
Purchasers. 
  

									
		 		 	Very truly yours,
					
	Dated:	 	____	 		 	By:	 	 
					
		 		 		 	Print Name:	 	 
					
		 		 		 	Title:	 	 

 APPENDIX III 

FORM OF REGISTRATION RIGHTS AGREEMENT 

See Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on April 23, 2010. 

 APPENDIX IV 

FORM OF OPINION OF LATHAM & WATKINS LLP 

1.         The Company is a corporation under the DGCL, with corporate power and
authority to enter into each of the Purchase Agreement, Registration Rights Agreement and Warrants (the “Transaction Documents”) and perform its obligations thereunder. With your consent based solely on certificates from public
officials, such counsel shall confirm that the Company is validly existing and in good standing under the laws of the State of Delaware and is qualified to do business in the State of California. 

2.         The execution, delivery and performance of each of the Purchase
Agreement and the Registration Rights Agreement has been duly authorized by all necessary corporate action of the Company and has been duly executed and delivered by the Company. 

3.         The execution, delivery and performance of the Warrants have been duly
authorized by all necessary corporate action of the Company and, when executed, issued and delivered to the Purchasers in accordance with the terms of the Purchase Agreement, will be the legally valid and binding obligations of the Company,
enforceable against the Company in accordance with their terms. 
 4.
        Each of the Purchase Agreement and the Registration Rights Agreement constitutes a legally valid and binding obligation of the Company, enforceable against the Company in accordance with its terms.

 5         The shares of Common Stock initially issuable upon exercise
of the Warrants (the “Warrant Shares”) have been duly authorized by all necessary corporate action of the Company. Assuming issuance of the Warrant Shares upon the exercise of the Warrants on the date hereof in accordance with the terms of
the Purchase Agreement and the Warrants, the Warrant Shares would be validly issued, fully paid and non-assessable and free of preemptive rights arising from the Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws of
the Company (the “Governing Documents”). 
 6.         The
execution and delivery of each of the Transaction Documents and the issuance and sale of the Warrants to the Purchasers pursuant to the Purchase Agreement do not on the date hereof: (a) violate the provisions of the Governing Documents;
(b) violate any federal or California statute, rule or regulation applicable to the Company, or the DGCL; (c) require any consents, approvals, or authorizations to be obtained by the Company from, or any registrations, declarations or
filings to be made by the Company with, any governmental authority under any federal or California statute, rule or regulation applicable to the Company on or prior to the date hereof; or (d) result in the breach of or a default under any of
the agreements identified to such counsel by an officer of the Company as material to the Company and listed on a schedule to such opinion, except for the registration rights pursuant to Sections 5 and 6 of the Amended and Restated Information and
Registration Rights Agreement dated May 8, 2001 by and among the Company and the investors named therein (the “2001 Agreement”) and the rights set forth in Section 12 of the 2001 Agreement, and the preemptive rights
pursuant to Section 8 of the Securities Purchase Agreement, dated October 12, 2009 (the “2009 SPA”), by and among the Company and the purchasers party thereto, which rights under the 2001 Agreement and the 2009 SPA were
respectively waived pursuant to the Waiver of Registration Rights and Notice of Registration Rights dated April 21, 2010 by and among the Company, Sutter Hill Ventures, a California Limited Partnership, Alta Biopharma Partners II, L.P., and
Alta Embarcadero Biopharma Partners II, LLC, and the Waiver of Preemptive Rights dated April 21, 2010 by and among the Company, the Purchasers, Alta Biopharma Partners II, L.P. and Alta Embarcadero Biopharma Partners II, LLC. 

7.         Assuming the accuracy of the representations and warranties of each of
the Purchasers contained in the Purchase Agreement, (a) no registration of the Warrants under the Securities Act of 1933, as amended, is required for the purchase of the Warrants by the Purchasers in the manner contemplated by the Purchase
Agreement and (b) no registration of the Warrant Shares under the Securities Act of 1933, as amended, would be required for the issuance of the Warrant Shares to the Purchasers upon exercise of the Warrants in accordance with the terms of the
Purchase Agreement and the Warrants, assuming such issuance and exercise took place on the date hereof. Such 
  

 1 

 
counsel shall express no opinion, however, as to when or under what circumstances any Warrants initially sold to the Purchasers by the Company or any Warrant Shares issued upon exercise of
Warrants may be reoffered or resold. 
  

 2 

 SCHEDULE OF EXCEPTIONS 

April 21, 2010 

This Schedule of Exceptions is being furnished by Corcept Therapeutics Incorporated, a Delaware corporation, (the
“Company”), to the Purchasers listed on Exhibit A to that certain Warrant Purchase Agreement of even date herewith by and among the Company and such Purchasers (the “Agreement”) in connection with the execution and
delivery of the Agreement, pursuant to Section 4 of the Agreement. Unless the context otherwise requires, all capitalized terms used in this Schedule of Exceptions shall have the respective meanings ascribed to such terms in the Agreement.

 This Schedule of Exceptions and the information, descriptions and disclosures included herein is intended to
set forth exceptions to the representations and warranties of the Company contained in the Agreement. The contents of all agreements and other documents referred to in a particular section of this Schedule of Exceptions are incorporated by reference
into such particular section as though fully set forth in such section. 
  

	4.9	     No Material Adverse Change 

During the period subsequent to December 31, 2009, there have been (i) changes in cash flows and results of
operations, (ii) stock option grants and (iii) increases in shares available under the 2004 Equity Incentive Plan, each of which transpired in the ordinary course of business and each of which has been disclosed to Purchasers. 

 

	4.11	     No Integrated Offering 

The following information is for provided for informational purposes only and does not constitute a representation or
warranty of the Company: 
 On March 30, 2007, the Company sold 9,000,000 shares of Common Stock in a
private placement under Rule 506 under the Securities Act to a total of 39 “accredited investors” (as defined in Rule 501 of Regulation D under the Securities Act) at a price of $1.00 per share, for aggregate proceeds of $9,000,000.

 On August 17, 2007, the Company sold 3,599,997 shares of Common Stock in a private placement under Rule
506 under the Securities Act to a total of 32 “accredited investors” (as defined in Rule 501 of Regulation D under the Securities Act) at a price of $2.10 per share, for aggregate proceeds of $7,599,999. 

On September 24, 2007, the Company sold 1,190,476 shares of Common Stock in a private placement under Rule 506 under
the Securities Act to one “accredited investor” (as defined in Rule 501 of Regulation D under the Securities Act) at a price of $2.10 per share, for aggregate proceeds of $2,500,000. 

On March 14, 2008, the Company sold 8,923,210 shares of Common Stock in a private placement under Rule 506 under the
Securities Act to a total of 31 “accredited investors” (as defined in Rule 501 of Regulation D under the Securities Act) at a price of $2.77 per share, for aggregate proceeds of approximately $25,000,000. 

During the quarter ended September 30, 2008, the Company sold 404,587 shares of Common Stock in private placements
under Rule 506 under the Securities Act to one “accredited investor” (as defined in Rule 501 of Regulation D under the Securities Act) at an average price of $1.85 per share, for aggregate proceeds of $750,000. 

On October 16, 2009, the Company sold 12,596,475 shares of Common Stock in a private placement under Rule 506 under
the Securities Act to a total of 43 “accredited investors” (as defined in Rule 501 of Regulation D under the Securities Act) at a price of $1.43 per unit (consisting of one share of Common Stock and .35 of a warrant to purchase one share
of Common Stock), for aggregate proceeds of approximately $18,000,000. 
 In addition to the sales of shares of
Common Stock on October 16, 2009, during the quarter ended December 31, 2009, the Company sold 102,149 shares of Common Stock in private placements under Rule 506 under the Securities Act to one “accredited investor” (as defined
in Rule 501 of Regulation D under the Securities Act) at an average price of $2.45 per share, for aggregate proceeds of $250,000. 
  

 1 

 During the quarter ended March 31, 2010, the Company sold 229,031
shares of Common Stock in private placements under Rule 506 under the Securities Act to one “accredited investor” (as defined in Rule 501 of Regulation D under the Securities Act) at an average price of $2.73 per share, for aggregate
proceeds of $625,000. 
  

 2Settlement Agreement

 Exhibit 10.1 

SETTLEMENT AGREEMENT 

(‘vaststellingsovereenkomst’) 

THE UNDERSIGNED: 
  

	1.	The company with private limited liability FEI ELECTRON OPTICS B.V., being registered in Eindhoven and having its office at Achtseweg Noord 5 building AAE in
(5651 GG) Eindhoven, the Netherlands (hereafter: “FEI Electron Optics”), in this matter lawfully represented by Mr. E.H.J. Kaerts, statutory Director, 

AND 
  

	2.	Mr. R.H.J. FASTENAU, residing at [address omitted] (hereafter: “Mr. Fastenau”). 

FEI Electron Optics and Mr. Fastenau together are also referred to as “Parties”. 

WHEREAS: 
  

	a.	Mr. Fastenau entered into service with (the legal predecessor of) FEI Electron Optics on 1 December 1981 and currently holds the position of Managing
Director, Executive Vice President Marketing and Technology under the conditions stipulated in the employment contract between the parties of 28 November 2006 (hereafter: the “Employment Contract”); 

 

	b.	Mr. Fastenau was appointed as statutory director of FEI Electron Optics pursuant to the articles of association and will voluntarily resign as statutory director
of FEI Electron Optics and any other directorships and/or (corporate) positions and/or power of attorney affiliated with the FEI group of companies, as laid down hereafter; 

 

	c.	Mr. Fastenau’s gross monthly base salary amounts to € 20,416.67 gross. 

 

	d.	Mr. Fastenau was born on [birth date omitted] and is therefore [age omitted] years old on the date this agreement is signed; 

 

	e.	FEI Electron Optics has informed Mr. Fastenau that it is aiming at a termination of the Employment Contract due to a significant unsolvable difference of opinion
about the strategy for the Corporate Technology group. It has informed Mr. Fastenau that it holds the opinion that he cannot remain in his position at FEI Electron Optics. Parties have discussed their differences and arrived at the conclusion
that fruitful cooperation in the future is no longer an option; 

  

	f.	FEI Electron Optics has indicated that no suitable alternative position is available for Mr. Fastenau within the organization of FEI Electron Optics, considering
the knowledge and experience of Mr. Fastenau; 

  

	g.	In the light of the aforementioned, FEI Electron Optics has taken the initiative to terminate the Employment Contract; 

	h.	Parties have come to an agreement with regard to the conditions of termination, which they hereby wish to lay down in writing; 

 

	i.	Mr. Fastenau confirms that he sought legal advice before signing this settlement agreement. 

AGREE AS FOLLOWS: 
  

	1.	The Employment Contract between the parties will end by mutual consent on December 31, 2010 (the “End Date”), except as otherwise set out below.

 The termination of the Employment Contract is not based on any urgent reason within the meaning of
Section 678 of Book 7 of the Dutch Civil Code [Burgerlijk Wetboek] for which Mr. Fastenau may be blamed. Neither has the employment contract been terminated by Mr. Fastenau or at his request. 

Mr. Fastenau voluntarily resigns from his appointment as director pursuant to the articles of association of FEI Electron Optics and
FEI Electron Optics International B.V. as of the date on which this agreement is signed (“Managing Director Status End Date”). As of the Managing Director Status End Date Mr. Fastenau will no longer serve as an officer or a
director of FEI Electron Optics or FEI Electron Optics International B.V. and he will sign the required forms to be removed from the Trade Register of the Chamber of Commerce. On the Managing Director Status End Date, Mr. Fastenau will also
resign from his director position he holds as a director of Phenom-World B.V. The FEI group of companies will effectuate the formal removal of directorships Mr. Fastenau holds within the FEI group of companies as of the Managing Director Status
End Date. In this respect, Mr. Fastenau will provide all reasonable assistance required for the removal of directorships he holds in the FEI group of companies. This includes the following positions: 

 

	 	-	Statutory director of FEI Electron Optics B.V. (The Netherlands) 

  

	 	-	Statutory director of FEI Electron Optics International B.V. (The Netherlands) 

As from 6 May 2010 and for the duration of Mr. Fastenau’s employment, the stock trading policy that applies to regular
employees will apply to Mr. Fastenau and he will no longer be considered an “insider” for purposes of the FEI group insider trading policy. 
  

	2.	Mr. Fastenau herewith grants as from the Managing Director Status End Date for each of the companies listed under article 1 above, unlimited power of attorney to
E.H.J. Kaerts, director and to any such person designated by Mr. Kaerts. To the extent permissible by the respective local laws, Mr. Kaerts shall have all and any authority with respect to each company or entity that Mr. Fastenau
currently has to represent and legally bind such company or entity. 

  

	3.	Mr. Fastenau’s salary will be paid as usual until the End Date. A final settlement will be effected as of the End Date. Any days’ holiday accrued but not
taken will be deemed to have been taken before the End Date. In other words, there will be no right to payment of such days. FEI Electron Optics shall fulfil its pension obligations pursuant to the applicable pension regulations of the PME
Pensioenfonds for the Metalektro and on the grounds of the Dutch Pension Act [Pensioenwet] until the End Date. 

	4.	For the period from the Managing Director Status End Date until the End Date, Mr. Fastenau shall be available for employment with FEI Electron Optics upon its
request and under the direction of Mr. Kania. As Mr. Fastenau remains employed by FEI Electron Optics until the End Date, he is not allowed to work for third parties, unless FEI Electron Optics gives written permission to do so.

 During this period, Mr. Kania may assign special projects to Mr. Fastenau. In addition,
Mr. Fastenau will be reasonably available for consultations and assistance concerning affairs at the FEI group of companies. The parties agree that the nature of Mr. Fastenau’s work will not be beyond the overall scope of his
experience, knowledge and expertise or require travel significantly more extensive than in which he has recently engaged. 
  

	5.	FEI Electron Optics will pay an overall amount of EUR 1,250,000,— gross (in words: one million two hundred fifty thousand Euro), which includes severance
compensation, possible future loss of pension, any bonus entitlements, possible loss of any stock grant that does not vest in time, days’ holidays, coaching, legal and/or outplacement fees, and any other payments or contributions. The amount
will be paid by FEI Electron Optics within 30 days to Mr. Fastenau of the End Date. Mr. Fastenau will be at liberty to indicate how he wants the said amount to be paid, provided that such is permissible under tax law and does not lead to
an increase in the costs for FEI Electron Optics, and provided that he produces the proper documents. In case Mr. Fastenau wants the said amount paid in a different way than his salary is usually paid, he shall inform FEI Electron Optics
thereof in a timely manner before the End Date. 

 After receiving a statement of expenses in the name of FEI
Electron Optics from Mr. Fastenau’s authorized legal representative and coach, FEI Electron Optics will pay the expenses Mr. Fastenau incurred for legal assistance and coaching. The amounts paid by FEI Electron Optics B.V. pursuant to
the statements received, including VAT, will be deducted from the overall amount of EUR 1,250,000,— gross as described above. 

In the event Mr. Fastenau dies before the End Date, the employment contract will terminate with immediate effect. FEI Electron Optics
covenants that the amount of EUR 1,250,000 gross mentioned above will be paid to the next of kin. This amount includes the statutory payment of one month salary due by FEI Electron Optics as described in Section 674 of Book 7 of the Dutch Civil
Code. 
  

	6.	Mr. Fastenau shall return any and all records and property made available to him within the framework of his position, including the leased car with its car and
insurance registration papers, car keys, fuel card, laptop, etc. to FEI Electron Optics in good condition at the End Date. Mr. Fastenau is fully entitled to use the company property until the End Date. 

The provisions of article 9.6 of the Employment Contract (payment lease break fee) shall not apply to the termination thereof pursuant to
this Settlement Agreement. 
  

	7.	Mr. Fastenau may exercise the currently exercisable stock option rights through the End Date (and up to 30 days after the End Date) in conformity with the FEI
group of companies Stock Option Plan and the regular employee trading policy described above. This also reflects the stock option rights that are going to vest in November 2010. 

FEI Electron Optics may set off the taxes and social-insurance contributions that have been or will be paid by it pursuant to statutory
regulations in connection with the stock options granted to Mr. Fastenau against any net salary payment to which he is entitled, or recover such from him in any other way. 

	8.	The parties shall observe absolute confidentiality in respect of third parties as to the contents of this agreement, unless the parties are required to disclose
information on the grounds of a statutory rule. In that case, the parties shall consult each other about this in advance. 

  

	9.	Parties agree not make any derogatory remarks concerning each other and any companies affiliated with FEI Electron Optics, or any of their officers, directors and
employees. This derogatory remarks restriction applies to the Parties’ communications with any and all persons, organizations and entities (whether public or private), except this restriction is not intended to bar truthful communications with
those government agencies that by law cannot be prohibited. Further, Parties agree not to initiate any contact with the press or other media regarding each other or any companies affiliated with FEI Electron Optics. 

Parties shall consult each other about the manner in which Mr. Fastenau’s resignation will be communicated both internally and
externally. 
  

	10.	Mr. Fastenau acknowledges that the Confidentiality clause as stipulated in article 10 of the Employment Contract and the Business Relations clause as stipulated in
article 13 of the Employment Contract (together: the “Post Contractual Obligations”) will remain in full force and effect even after the End Date. Mr. Fastenau hereby agrees to abide by the terms of those Post Contractual Obligations.
For the sake of clarity, subject to the conditions contained herein, Mr. Fastenau expressly acknowledges that all his obligations under the Employment Contract continue through the End Date. FEI Electron Optics reserves all rights to enforce
the provisions of the Employment Contract. The obligations under the Business Relations clause as described above shall commence per the End Date. 

Except with respect to the Post Contractual Obligations, once the obligations set forth above have been fulfilled, FEI Electron Optics and
any companies affiliated with it, on the one hand, and Mr. Fastenau, on the other, will have no more additional obligations in respect of each other on the basis of the Employment Contract, its termination, or on any other basis whatsoever, and
the parties shall grant each other final discharge in this regard under any and all jurisdictions and under all local or foreign law. 

The corporate discharge of Mr. Fastenau’s responsibilities as director pursuant to the articles of association of FEI Electron
Optics and FEI Electron Optics International B.V. will however have to take place in accordance with the appropriate corporate proceedings. The full and final discharge does therefore explicitly not include Mr. Fastenau’s corporate (and/or
functional) relationships with FEI Electron Optics and/or FEI Electron Optics International B.V. FEI Electron Optics shall however procure that Mr. Fastenau will be granted corporate discharge as described above. 

 

	11.	In the event that an Article of this Settlement Agreement is invalid, illegal, not binding, or unenforceable (either in whole or in part), the remainder of this
Settlement Agreement shall continue to be effective to the extent that, in view of the Settlement Agreement’s substance and purpose, such remainder is not inextricably related to and therefore inseverable from the invalid, illegal, not binding
or unenforceable provision. Parties shall make every effort to reach agreement on a new Article which differs as little as possible from the invalid, illegal, not binding or unenforceable Article, taking into account the substance and purpose of
this Settlement Agreement. 

	12.	The foregoing qualifies as a settlement agreement within the meaning of Section 900 of Book 7 of the Dutch Civil Code. 

 

	13.	Dutch law shall apply to this Settlement Agreement and to the interpretation of it. 

Drawn up in triplicate originals and signed on
                    . 
  

									
	  
	 		 		 		 	  

	  
 FEI Electron Optics
	 		 		 		 	  
 Mr. R.H.J. Fastenau

	Mr. E.H.J. Kaerts, statutory Director	 		 		 		 	

 Signature for agreement with paragraph 3 of article 1 and paragraph 2 of article 10: 

 

	
	  

	  
 FEI Electron Optics International B.V.

	Mr. E.H.J. Kaerts, statutory Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00172-of-00352.parquet"}]]